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ABSTRACT 
Maternal stress response, micronutrient deficiency and maternal immune 
activation have all been implicated in the etiology of autism spectrum disorders (ASD). 
We evaluated several maternal factors that might act through one or more of these 
mechanisms. Specifically, we assessed the independent effects of maternal illness 
before and during pregnancy (Study 1) and maternal pre-pregnancy obesity (Study 2) on 
the risk of ASD using a case-control design among patients born into the General 
Practice Research Database from 1993-2008. We also assessed the effects of short 
interpregnancy interval and maternal history of pregnancy loss (Study 3) on the risk of 
ASD through age 3 years using a cohort design among individuals born to multigravida in 
Massachusetts from 2000-2010. Conditional logistic regression (Studies 1 and 2) or log-
binomial regression models (Study 3) were used to analyze the data. 
In study 1, we found modest associations with maternal bacterial infection (aOR: 
1.5, 95% Cl : 1.1, 2.0) and asthma (aOR: 1.3, 95% Cl: 1.1, 1.5), which were consistent 
across the ASD subtypes. No association was found between maternal autoimmune 
disease and ASDs. 
iv 
In study 2, we observed a nonlinear association between maternal BMI and ASD 
that suggested extremes in maternal BMI (underweight and obesity) are associated with 
modest increases in the risk for ASD among offspring. 
In study 3, we found a non-linear association with IPI, where IPI lengths less than 
18 months and longer than 60 months were associated with an increased risk for ASD. 
This association was restricted to consecutive live births and stronger for younger 
mothers than older mothers. A history of pregnancy loss among multigravida was also 
associated with a modest increase in ASD risk. 
Together these findings contribute important information about the etiology of 
autism spectrum disorders and provide additional support for the maternal immune 
activation and nutritional depletion hypotheses. 
v 
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1. INTRODUCTION 
Autism spectrum disorders (ASD) are a heterogeneous group of 
neurodevelopmental disorders diagnosed solely based on presentation of a complex 
behavioral phenotype characterized by core deficits in three symptom domains: social 
interaction, communication, and repetitive behavior (1). The DSM-IV-TR provides the 
current diagnostic criteria for autism spectrum disorders in three subtypes autistic 
disorder, Asperger's disorder, and pervasive developmental disorder not otherwise 
specified (POD-NOS). A diagnosis of autistic disorder requires at least two deficits in 
social interaction, at least one deficit in communication, and at least one repetitive 
behavior with an onset of delays prior to age three (2). Diagnostic criteria for Asperger's 
disorder include at least two deficits in social interaction and at least one repetitive 
behavior with no accompanying delay in age-appropriate language or cognitive 
development (2). The category of PDD-NOS is used when there is a severe and pervasive 
impairment in reciprocal social interaction associated with impairment in either verbal 
or nonverbal communication skills or with repetitive behavior, but the criteria are not 
met for a specific pervasive developmental disorder. Autism is usually diagnosed by 3 
years of age, but the symptoms are often noticeable by 9 months (3). Individuals with 
Asperger's syndrome are generally diagnosed in later childhood or early adolescence 
(3) . 
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The prevalence of ASD has risen from less than 20 per 10,000 persons in the 
1980's (4) to more recent estimates as high as of 1 in 91 among 3- to 17-year old (5) and 
1 in 191 among 8-year old children (1). It is believed that the "autism epidemic" is at 
least partially explained by a broadening case definition and improvements in 
awareness by the both clinicians and the public leading to more complete 
ascertainment (6). Studies showing increases in autism incidence by successive birth 
cohorts that are more prominent for high- than low-functioning children lend support to 
this explanation (7). A recent autism surveillance report from California showed autism 
prevalence has yet to plateau and concluded that about two-thirds of the increase is 
explained by earlier age at diagnosis and inclusion of milder cases, but the extent to 
which the continued rise might represent a real increase in occurrence is unclear (8). 
The causal mechanisms underlying ASD are to a large extent unknown, but 
research supports a strong genetic component. There is high recurrence within families 
- the risk for autism is 25 times higher for a child whose sibling has autism (9). Twin 
studies have demonstrated much higher concordance in monozygotic twins (70-90%) 
than in dizygotic twins (0-10%) (10). Numerous studies have identified gene mutations 
and have shown that structural variations in any of several genes can increase autism 
risk (9). While several defined single gene mutations, rare genetic syndromes, and de 
novo copy number variation have been identified for autism, none occurs in more than 
1-2% of cases (9). This together with the incomplete concordance in monozygotic twins 
indicates a role of environmental factors. 
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Key pathophysiologic changes observed in the brain of autistic individuals 
suggest that autism begins during fetal development (11, 12). The fetal programming 
hypothesis states that the environment in utero can alter the development of the fetus 
with a permanent effect on phenotype. There are a number of plausible theories 
supporting how maternal factors might influence autism risk in offspring. First, fetal 
environment can be altered by maternal stress through changes in her hormonal profile, 
namely increased circulating cortisol (13). Animal studies suggest prenatal stress might 
induce the activity of the hypothalamic-pituitary-adrenal (HPA) axis leading to neuronal 
damage via excess release of proinflammatory factors (13). Maternal prenatal stress can 
also reduce uterine and placental circulation causing fetal hypoxia and pregnancy 
complications (14). What constitutes stress is unclear and is likely to vary across women 
but studies examining maternal exposure to bereavement, natural disaster, and famine 
with respect to neurodevelopmental outcomes in offspring have found mixed results 
(14, 15). 
Maternal nutritional status might also influence the fetal environment through 
mechanisms other than stress. The fetus is reliant on the mother for the micronutrients 
and growth factors required for normal brain development. Certain nutrients, such as 
polyunsaturated fatty acids, iron, zinc, vitamin A and folate, have greater effects on 
brain development than do others. Insufficiency or overabundance, depending on the 
specific nutrient, can directly result in altered myelination, hippocampal and cerebellar 
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development and synapse formation (16). Fatty acids also have complex effects on 
inflammatory markers, which could also influence neural development (17). 
Finally, a recent mechanistic hypothesis was proposed based on mounting 
evidence from animal experiments and human studies that suggest activation of the 
maternal immune system may be a risk factor for autism (18). Specifically, it suggests 
that elevated maternal pro-inflammatory cytokines pass to the fetal circulation and 
cross the fetal blood-brain barrier. This maternal'cytokine storm' may result in a chronic 
inflammatory environment causing abnormal neuronal growth and differentiation 
within the fetal brain. 
The following dissertation evaluates several maternal factors that might act 
through one or more of these described mechanisms to cause autism in offspring. 
Specifically, I assess the independent effects of maternal illness before and during 
pregnancy (Study 1) and maternal pre-pregnancy body mass index (Study 2) on the risk 
of ASD using a case-control design among patients born into the UK-based General 
Practice Research Database from 1993-2008. I also assess the effects of maternal 
reproductive factors, including interpregnancy interval and history of pregnancy loss 
(Study 3} on the risk of ASD through age 3 years using a cohort design among individuals 
born to multigravida in Massachusetts from 2000-2010. 
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2. THE ASSOCIATION BETWEEN MATERNAL ILLNESS AND THE OCCURRENCE OF 
AUTISM SPECTRUM DISORDERS AMONG OFFSPRING: A CASE-CONTROL STUDY 
2.1. ABSTRACT 
Maternal autoimmune dysfunction and maternal immune activation may affect the fetal 
environment causing deficiencies in fetal neurodevelopment. Few studies have 
evaluated the relationship between maternal illness and the autism spectrum disorders 
(ASD) and none have had the ability to explore ASD subtype specific associations. We 
assessed the associations of maternal infection, asthma and autoimmune disease with 
the occurrence of ASD among singletons born into the UK General Practice Research 
Database from 1993 through 2008. Case subjects were children with a diagnosis on the 
autism spectrum. Up to four control subjects were matched to each case subject on 
birth year, sex, and general practice. Conditional logistic regression was used to 
calculate crude and multivariable adjusted odds ratios for any ASD and for specific ASD 
subtypes. While analysis of the full study population did not identify any significant 
relationships between maternal infection and autism spectrum disorders, a sensitivity 
analysis suggested a modest association with bacterial infection (aOR: 1.5, 95% Cl: 1.1, 
2.0), in particular skin and urinary tract infections. We also observed a small increase in 
ASD risk in relation to maternal asthma (aOR: 1.3, 95% Cl: 1.1, 1.5), which was 
consistent across the ASD subtypes. No association was found between maternal 
autoimmune disease and ASDs overall, but subtype specific analyses suggested a small 
increase in Asperger's disorder (aOR: 1.5, 95% Cl: 0.9, 2.5). Although the maternal 
7 
illnesses we evaluated in general are unlikely to contribute significantly to the 
development of ASD in offspring, some specific conditions may confer a small increased 
risk. 
2.2. INTRODUCTION 
Animal studies show that maternal immune activation disrupts fetal brain development 
via an increase in pro-inflammatory cytokine concentrations and suggest a differential 
vulnerability by gestational timing of exposure to the cytokine surge (1-6). Rodent 
models demonstrate that the maternal immune response to infection during critical 
prenatal periods of neurogenesis can cause lasting autistic-like behavioral changes in 
offspring (3, 7-9). Case reports and small epidemiologic studies suggest that maternal 
reported prenatal viral infections including rubella virus, cytomegalovirus, influenza and 
syphilis are associated with the development of ASD in the offspring (10-13). More 
recently, Atladottir et al. (14) utilized the Danish Medical Register to assess ASD 
occurrence in relation to maternal infections requiring hospitalization (overall, and 
separately for bacterial, viral and organ-specific infection categories) by trimester of 
pregnancy. They found ASD to be associated with maternal viral infection in the first 
trimester (aHR: 2.98; 95% Cl 1.29-7.15) and a weaker association with maternal 
bacterial infection in the second trimester (aHR: 1.42, 95% Cl 1.08, 1.87). 
Epidemiologic studies also suggest that children with ASD have a greater 
frequency of family history of autoimmune disorders with mothers being those most 
often affected (15-18). While studies examining maternal autoimmune disease have not 
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found an increased risk for ASD when all autoimmune diseases are combined, significant 
associations have been found for specific conditions such as type-1 diabetes, idiopathic 
thrombocytopenic purpura, myasthenia gravis, ulcerative colitis, rheumatoid arthritis, 
psoriasis and celiac (15, 17, 19-21}. However, there has been little overlap in the results 
between studies as to the specific maternal conditions associated with an elevated risk 
for autism. One previous study evaluated two immune-mediated conditions, maternal 
asthma and allergies, in addition to autoimmune disease and identified an elevated risk 
for ASD in relation to maternal asthma (17). Some studies were based on parental self-
reported autoimmune disease and none has evaluated ASD subtype specific 
associations. 
In the current study, we utilized the General Practice Research Database, a large 
population-based medical resource, to corroborate findings of others with respect to 
increases in ASD in relation to maternal asthma and autoimmune disease. We also 
evaluate whether the increase in risk observed by Altadottir et al. (14) for bacterial and 
viral infections requiring hospitalization may be extended to less severe infections. 
2.3. METHODS 
2.3.1. Data Source 
This study utilized data derived from the UK General Practice Research Database (GPRD) 
maintained by the Boston Collaborative Drug Surveillance Program (BCDSP) (22). The 
GPRD is a primary care database containing anonymized records for nearly 4 million 
active patients (about 6% of the UK population) from 450 general practices (23). GPRD 
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data are recorded using standardized software and a comprehensive coding system (i.e., 
the hierarchical Read code classification system (24)) by trained general practitioners. 
Participating general practices not only record each episode of illness and medical 
diagnoses, but also history and symptoms; clinical contacts; examination findings; 
preventive, operative and therapeutic procedures; test results; drug prescriptions; and 
referrals to specialists, outpatient clinics, and hospital admissions with the associated 
diagnoses. Additional patient information such as height, weight, and lifestyle habits 
such as smoking and drinking are also recorded . GPRD members have both a unique 
individual identification code and a family code. A mother's records can be matched to 
offspring records based on family identification number, GP practice code, infants birth 
month and year, and mother's pregnancy outcome date (25, 26). 
Validation studies have determined most of the diagnoses coded in the GPRD 
electronic record to be highly accurate (i.e., a median of 90% of cases confirmed) when 
compared against GP questionnaire responses, medical records held at the GP practice, 
or hospital letters, with diagnoses of chronic illness being somewhat more accurate than 
those of acute illness (22, 23, 27). A high consistency between the date of onset of 
disease recorded in the GPRD electronic medical record and the GP reported date has 
been demonstrated (27). 
A recent expert review of GPRD computerized records of ASD against all relevant 
available clinical reports including GP notes, consultant, speech therapy and educational 
psychologist reports, verified over 92% of diagnoses (27, 28). Additionally, the start of 
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the first trimester of pregnancy can be reliably identified for many of the mother-
offspring matched pregnancies, thus permitting the study of the effects of maternal 
prenatal and early pregnancy exposures on the development of offspring (25, 26). 
2.3.2. Study Population 
All ASD cases and non-ASD controls were identified from a source population consisting 
of all singleton live births who were registered with the GPRD at birth from 1993 
through 2008 and whose records were successfully matched to a mother with one or 
more years of recorded history in the database before the estimated start of pregnancy. 
Cases were identified as those with a first diagnosis for a developmental disorder on the 
autism spectrum from birth through 2010 (Read Codes: E140.00, E140000, E140.12, 
E140.13, E140z00, Eu84000, Eu84011, Eu84012, Eu84z11, Eu84500, Eu84100, Eu84y00, 
and Eu84yOO). 
Following a review of their entire GPRD record, cases were classified into groups 
representing the following ASD subtypes: autistic disorder, Asperger's disorder and 
other. The "Other" category included subjects diagnosed as PDD-NOS or more generally 
as having an autism spectrum disorder. If the diagnosis for an individual case changed 
over time the most recent diagnosis was used to determine ASD-subtype. Up to four 
random control subjects with no diagnosis for any ASD were matched to each case on 
year of birth, sex, and general practice. 
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2.3.3. Determination of Pregnancy Start Date 
For approximately half of the study population (50.9% of cases and 49.9% of controls), 
the date of the last menstruation (LMP) was recorded in the maternal GPRD record and 
was considered the start of the study pregnancy. The LMP date for the study pregnancy 
was estimated for the remaining women using the following algorithm. If there was an 
estimated date of delivery (EDD) recorded then the LMP was calculated as the EDD 
minus 280 days. Otherwise, the LMP was estimated as the actual date of delivery minus 
280 days. The pregnancy duration was then calculated as the delivery date minus the 
estimated start date of the study pregnancy. If there was a code for preterm associated 
with the study pregnancy but the calculated pregnancy duration was consistent with a 
term pregnancy, then the mother and child electronic medical records were reviewed 
manually to identify the earliest record for the pregnancy to determine a more 
appropriate estimate of the pregnancy start date. The algorithm-assigned start dates 
were also verified manually against the mother and child GPRD records for all subjects 
for whom the calculated pregnancy duration was less than 37 weeks. 
2.3.4. Maternal Illness 
Unique diagnoses of infection, asthma or autoimmune disease occurring before, during, 
and up to one year postpartum (for asthma and autoimmune disease only) were 
identified for each case and control subject. 
We identified all diagnoses for maternal infections from 3 months before the 
start of the study pregnancy through the end of the pregnancy and whether infection 
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was diagnosed pre-pregnancy (during the 3 months before the LMP), in the first 
trimester (from LMP through 92 days post-LMP), second trimester (from 93 days 
through 184 days post-LMP), or third trimester (from 185 days post-LMP through the 
delivery date). Infections were than classified as viral or bacterial and into the following 
system-specific categories: infectious enteritis, respiratory, skin, urinary tract, genital 
(not including STI's) and sexually transmitted infections. 
We identified all first diagnoses for asthma and autoimmune diseases from each 
mother's GPRD record. Specific autoimmune diseases included in our definition were 
chosen based on previous studies on their relationship with ASD. A complete list of the 
specific conditions included in our exposure definition is provided in Table 2.1. If 
mothers had more than one autoimmune condition they were include in the analysis for 
each of those conditions. 
Asthma and autoimmune disease were separately classified as: any exposure 
through one year after the delivery date and by timing of initial diagnosis including 
historic (any time prior to the LMP), l 5t trimester, 2nd trimester and 3rd trimester. 
Specific maternal autoimmune diseases, infection categories and exposure time 
windows were explored if there were at least 5 exposed case and 5 exposed control 
subjects. 
2.3.5. Covariates 
Potential confounders were identified a priori based on a review of the literature. In 
addition to the matching factors, we abstracted information on maternal pre-pregnancy 
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body mass index (underweight, normal weight, overweight, obese), maternal age, pre-
pregnancy smoking status recorded nearest to the LMP (coded as current, past, never, 
unknown), pre-pregnancy histories (yes, no) of alcoholism, drug abuse, and depression, 
antenatal folic acid prescriptions (yes, no), asthma medication prescriptions (yes, no), 
and prescriptions for medications commonly used to treat autoimmune disease (yes, 
no). Since maternal body mass index (BMI) is reported variably in the GPRD, we 
evaluated BMI measurements recorded nearest to and within the two years before the 
start of the study pregnancy (approximately 55% of cases and controls had a BMI 
recorded within this window) as well as those recorded within 10 years before the start 
of the pregnancy (approximately 77% of cases and controls had measurement within 
this broader window). Since model results were similar following adjustment for either 
variable, we present findings using the broader window in order to preserve power. 
2.3.6. Statistical Analysis 
Descriptive analyses were performed to determine the distribution of covariates 
(frequency and percent for categorical variables and mean and standard deviation for 
continuous variables) for cases and controls, and by status of maternal periconceptional 
infection, asthma and autoimmune disease among controls. 
Conditional logistic regression methods were used to calculate unadjusted odds 
ratios (OR) controlling for matched variables only and multivariable adjusted ORs and 
associated 95% confidence intervals for ASD (and specific ASD subtypes, where possible) 
in relation to each of the maternal illnesses of interest. Separate multivariate models 
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were developed for each primary exposure (1) any infection, (2) asthma and (3) any 
autoimmune disease, these models were then applied to each corresponding sub-
analysis (i.e., analyses of timing of diagnosis, specific infections and specific autoimmune 
diseases). To identify the set of covariates to be included in the final adjusted model for 
each primary exposure, covariates were independently added to the unadjusted model 
and the variable with the largest change in OR for the exposure of interest (infection, 
asthma, or autoimmune disease) among those exhibiting a change of >10% was 
retained. A similar process was employed with successive models until further inclusion 
of additional covariates resulted in a change in OR that was less than 10%. Since none 
of the individual covariates tested met the definition of confounder, we present results 
only for the unadjusted and the fully adjusted models. Subjects with no indication of 
infection in the 3 months before through the end of the study pregnancy who also had 
no documented history of asthma or autoimmune disease from the start of their GPRD 
record through the end of the study pregnancy were considered the reference for all 
comparisons. Subjects with missing covariate information were excluded from 
multivariable regression models. 
2.3.7. Sensitivity Analyses 
Misclassification of the timing of the diagnosis of maternal illness could occur since the 
LMP for many mothers was estimated; therefore, we completed analyses restricted to 
mothers with a GP-recorded LMP. We also performed a sub-analysis restricting the pre-
pregnancy diagnoses of asthma and autoimmune disease to those recorded within the 
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two years before the start of the study pregnancy to determine if disease diagnosed 
closer to the start of the pregnancy was more strongly associated with ASD occurrence 
in offspring than older diagnoses. 
2.4. RESULTS 
2.4.1. Population Characteristics 
Approximately, 84% of individuals with a diagnosis on the autism spectrum were able to 
be matched to their mother, a rate similar to that observed among all births into the 
GPRD. We identified a total of 2207 individuals with a diagnosis on the autism 
spectrum, of which 70.1% were diagnosed with autism, 26.4% were diagnosed with 
Asperger's disorder, and 3.4% were diagnosed with PDD-NOS or more generally as 
having an autism spectrum disorder. ASD cases were predominantly male (82.5%) 
independent of subtype. There were 8816 control subjects identified from the same 
source population as the ASD case subjects. 
Distributions of selected characteristics among ASD case and non-ASD control 
subjects are presented in Table 2.2. Case mothers tended to be slightly older than 
control mothers (18.5% of case mothers versus 15.7% of control mothers were 35 years 
or older at the start of the study pregnancy), were more likely to be obese (12.0% of 
case mothers versus 8.8% of control mothers), and were somewhat more likely to have 
a history of depression (17.8% of case mothers versus 13.0% of control mothers) or drug 
abuse (0.8% of case mothers versus 0.5% of control mothers). In general, these trends 
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were similar for both autistic disorder and Asperger's disorder cases compared to 
controls. 
Distributions of selected characteristics by status of maternal periconceptional 
infection, asthma and autoimmune disease among controls are presented in Table 2.3. 
Mothers with diagnoses for infection, asthma or autoimmune disease were more likely 
to be obese and to have a history of depression or drug abuse compared to those with 
none of the illnesses of interest. Mothers with asthma or autoimmune disease were also 
more likely to be ever smokers. Mothers with diagnoses for the any of the illnesses of 
interest had more antenatal appointments and more antenatal prescriptions than more 
healthy mothers. 
2.4.2. Maternal Infection and Autism Spectrum Disorders 
The frequencies of infection from 3 months before the start of the study pregnancy until 
the delivery date are provided in Table 2.4. Overall, similar proportions of case and 
control mothers had diagnoses of infections before and during the study pregnancy. 
Mothers of children with Asperger's were slightly more likely to have been diagnosed 
with infections than control mothers and mothers of children with autistic disorder. 
Results from conditional regression analyses of the association between 
maternal infection and ASD among offspring are presented in Table 2.5. None of the 
variables assessed were meaningful confounders of the observed associations as 
evidenced by effect estimates that were essentially unchanged following adjustment for 
maternal age, pre-pregnancy BMI, depression, smoking status, alcoholism, drug abuse, 
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and folic acid prescriptions. For the occurrence of ASDs overall, no significant 
associations were observed in relation to maternal infection (combined or by more 
specific infection categories). Odds ratios ranged from 0.9 (95% Cl: 0.4, 1.7) for sexually 
transmitted infections to 1.1 (95% Cl: 0.9, 1.4) for urinary tract infections. Separate 
analyses for the specific ASD subtypes revealed no association between maternal 
infection and autistic disorder, but suggested possible increases in Asperger's disorder 
with maternal infectious enteritis (aOR: 3.4, 95% Cl: 0.9, 12.8) and maternal skin 
infection (aOR: 2.2, 95% Cl: 0.8, 5.9). There were no notable differences in any of the 
time periods for any of the infection types (Table 2.6), with the exception of a suggested 
association with maternal pre-pregnancy urinary tract infection (aOR: 1.6, 95% Cl : 0.9, 
2.8). 
2.4.2.1. Sensitivity Analyses 
Findings from a sensitivity analysis restricted to pregnancies with a GP-recorded LMP 
are presented in Tables 2.7 and 2.8. These analyses revealed a modest association 
between maternal bacterial infection and ASD among offspring (aOR: 1.5, 95% Cl: 1.1, 
2.0), which was consistent across the two subtypes. Urinary tract infections were 
significantly associated with an increase in ASD overall (aOR: 1.6, 95% Cl: 1.1, 2.3), and 
autistic disorder specifically (aOR: 1.7, 95% Cl: 1.1, 2.5). There were also suggestive 
increases in ASD risk in relation to skin infection (aOR: 1.6, 95% Cl: 0.9, 2.9). Analysis by 
timing of infection showed an elevated risk for ASD with maternal bacterial infections 
diagnosed in either early (i.e. in the 3 months before the start of the pregnancy and in 
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the first trimester) or late (i.e. in the third trimester) pregnancy, particularly for skin and 
urinary tract infections. 
2.4.3. Maternal Asthma and Autoimmune Disease and Autism Spectrum Disorders 
The frequencies of asthma and autoimmune diseases diagnosed before the start of the 
study pregnancy through one year after the delivery date are provided in Table 2.9. 
Compared to control mothers, ASD case mothers, particularly mothers of children with 
Asperger's disorder, were slightly more likely to have an asthma diagnosis. Overall, 
similar proportions of ASD case and control mothers had a diagnosis for any 
autoimmune disease. 
Results from conditional regression analyses of the association between 
maternal asthma or autoimmune disease and ASD among offspring are presented in 
Table 2.10. Maternal asthma was associated with a small increase in ASD among 
offspring (aOR: 1.3, 95% Cl: 1.1, 1.5) that did not differ substantially by ASD subtype. 
Maternal autoimmune diseases were not associated with ASD occurrence overall, 
adjusted odds ratios for specific autoimmune diseases ranged from 0.4 (95% Cl: 0.2, 1.2) 
for palsies to 2.2 (95% Cl: 0.6, 7.9) for ankylosing spondylitis. ASD subtype specific 
analyses suggested a small increase in Asperger's disorder in relation to maternal 
autoimmune disease overall (aOR: 1.5, 95% Cl: 0.9, 2.5). 
Analysis by timing of asthma and autoimmune diagnosis are presented in Table 
2.11. The vast majority (over 80%) of asthma and autoimmune disease diagnoses 
occurred before the start of the study pregnancy. The association between maternal 
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asthma diagnosed prior to the start of the study (aOR: 1.3, 95% Cl: 1.1, 1.6) was similar 
to that observed overall for any asthma diagnosis. No significant associations were 
identified for autoimmune diseases diagnosed in any of the time intervals considered. 
2.4.3.1. Sensitivity Analyses 
When we restricted the analyses to first diagnoses of asthma or autoimmune disease 
recorded within the two years before the start of the study pregnancy through one year 
after the delivery, overall results were similar to those including all historic diagnoses, 
but less precise (Table 2.12). Additionally, results were unchanged when analyses were 
confined to pregnancies with a GP-recorded date for the LMP (Table 2.13). 
2.5. DISCUSSION 
Overall, our findings suggest that the maternal illnesses we evaluated are unlikely to 
contribute significantly to the development of ASD in offspring. While the primary 
analysis of the full study population did not identify any significant relationships 
between maternal infection and autism spectrum disorders, a sensitivity analysis 
suggested a modest association with bacterial infection, particularly skin and urinary 
tract infections. We did not identify any statistically significant associations with 
autoimmune disease. However, we found maternal asthma to be associated with a 
small 20-30% increase in ASD, regardless of subtype. 
Approximately 38% of controls in our study had an infection around the time of 
pregnancy; this is higher than the rate of 1.3% reported for infection requiring 
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hospitalization (14), and lower than estimate of 64% based on maternal self-report (29). 
Our finding relating bacterial infections early and late in pregnancy to an increase in ASD 
risk supports those of others. A large population-based study in Denmark found a similar 
increase in ASD in relation to admission to hospital in the second trimester due to 
maternal bacterial infection (OR: 1.4, 95%CI: 1.1, 1.9) (14). The reason for the 
differences in the exposure sensitive time windows between the studies is unclear, but 
may be related to differences in the study designs in that the timing of hospitalization 
for infection may not always parallel the onset of illness. With respect to specific 
infections, we identified an increased risk for ASD in relation to skin and urinary tract 
infections. Maternal urinary tract infections during pregnancy were previously 
identified as a potential risk factor for infantile autism in a small exploratory case-
control study (30). A population-based study of maternal health and intellectual 
disability (ID) found maternal pre-pregnancy renal and urinary conditions, such as 
urinary tract infections, to be associated with an increased risk for mild to moderate ID 
(31), which co-occurs in 70% of ASD (32). Results from the Denmark study discussed 
above suggest an elevated risk for ASD with maternal second trimester skin infections 
(OR: 2.1, 95% Cl: 0.9, 5.1), but the finding was not statistically significant (14). 
Unlike some others (14, 33), we did not observe an association between 
maternal viral infections during pregnancy and autism. Maternal measles, mumps and 
influenza have each been reported as possible risk factors for autism (14, 33) . Clinical 
symptomology of these and other viral infections includes fever, which has also been 
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associated with an elevated risk for autism (30, 34). Recently, the risk of 
neurodevelopmental disorders in relation to maternal influenza and fever was 
investigated in the CHARGE study, a population-based case-control study in California. 
While influenza was not found to be associated with ASD, there was an increased risk 
for ASD in relation to fever (34). However, stratification by maternal use of anti-pyretic 
medications revealed that only untreated fever was associated with an increased risk 
(OR: 2.6, 95% Cl: 1.3, 5.0). This finding suggests that the increased risk in relation to 
viral infection identified by others may actually be confounded by maternal fever. 
Although we were not able to control for fever as it is not reliably captured in the GPRD, 
we may not have detected an association with viral infection because mothers in our 
study population may have been more likely to be treated for a fever given the nature 
of our data source. 
Our finding of an association with maternal asthma is consistent with those of 
others who identified an elevated risk of ASD (17) and mild to moderate ID (31) in 
relation to pre-pregnancy asthma diagnoses. Croen et al. (17) also found that asthma 
diagnoses, regardless of timing of diagnosis, were associated with an increase in ASD, 
particularly in families with more than one ASD-affected child . 
The prevalence among our control mothers for autoimmune disease overall and 
for specific conditions including alopecia areata, diabetes, rheumatoid arthritis, 
inflammatory bowel disease and vitiligo was similar to that reported by Croen et al. (17). 
We did not expect to identify an association with autoimmune diseases overall given 
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their variable pathogenesis; however, we did not identify significant increases for any of 
the individual conditions examined. Since an association has been observed by others 
(20, 31), it is worth noting that the odds ratio for ASD in relation to maternal diabetes 
was elevated, though not significantly. There has been little overlap in the results across 
studies as to the specific maternal autoimmune conditions identified as potential risk 
factors, but associations have been reported with ulcerative colitis (21), psoriasis (17), 
myasthenia gravis (20), and rheumatic fever (20). Unlike our evaluation, most previous 
studies did not restrict their assessment to autoimmune disease diagnosed around the 
time of pregnancy. One possible mechanism for an association between autoimmune 
disease and ASD is a shared genetic susceptibility to immunologic diseases and autism 
(35-37), in which case our exclusion of diagnoses made long after the study pregnancy 
could have limited our ability to detect an association. 
The observed associations with both maternal asthma and bacterial infection in 
relation to ASD among offspring are biologically plausible based on mounting evidence 
from animal experiments and human studies, which suggests that activation of the 
maternal immune system may be a risk factor for autism (38). Inflammatory cytokines 
are elevated in response to immune system activation. These proteins act as critical 
mediators of the pathogenic effect in some diseases and they coordinate the immune 
response necessary for resolving bacterial infection (39). Additionally, individuals with 
asthma have elevated serum and tissue concentrations of certain cytokines, which are 
implicated in the inflammation response associated with airway remodeling (39). Under 
23 
normal physiological conditions, these same cytokines are present in the fetus in low 
concentrations and play an important role in all phases of central nervous system 
development, including the regulation of axonal guidance, synapse formation and 
elimination, and survival, proliferation, and growth of neuronal and glial cells (40). 
Following maternal immune activation (e.g. infection, asthma flare-up), maternal 
cytokines may pass to the fetal environment via the placenta or cause induction of fetal 
inflammatory cytokines leading to higher circulating cytokine concentrations in the fetus 
(38, 40). Research suggests that even small disruptions to normal homeostatic cytokine 
concentrations can lead to aberrant neurodevelopment (1-4, 6-9, 38, 40). 
Our study consisted of a large sample of cases and matched controls in which all 
information was recorded prospectively by trained medical personnel, thus excluding 
the opportunity for recall bias. The use of primary care database of longitudinal medical 
records as our source population also minimized self-selection bias since case and 
control mothers did not volunteer to participate. 
Despite its strengths, our results should be considered in light of some potential 
limitations. Cases were identified exclusively by diagnostic Read codes and were not 
verified by standardized clinical assessment, which may have led to some 
misclassification and an attenuation of the observed associations. However, a recent 
review of GPRD computerized records of ASD against all available clinical reports 
verified over 90% of diagnoses (28), suggesting over-ascertainment was low. Still, our 
control population may have included a small number of children with undiagnosed 
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ASD. In our analyses by timing of illness and of specific infection and autoimmune 
diagnoses, particularly for ASD subtypes, some exposure categories included small 
numbers of cases and controls and sample size limitations may have precluded our 
ability to detect a true association. Misclassification of the timing of maternal illness 
before and during pregnancy also may have occurred since the LMP for about half of 
case and control mothers was approximated based on the date of delivery for the study 
pregnancy. In a sub-analysis restricted to mothers with a GP-recorded LMP date, results 
for asthma and autoimmune disease did not differ from the full analysis suggesting this 
misclassification did not explain this result. That the associations with asthma and 
autoimmune disease were unchanged based on this restriction is not surprising since 
the great majority of these diagnoses occurred well before the start of the study 
pregnancy. In contrast, associations between maternal infection and ASD were only 
apparent following this restriction suggesting that misclassification of exposure 
obscured associations in analyses of the full study population. We did not adjust for 
multiple comparisons; thus, the significant findings we identified may be due to chance. 
In conclusion, these findings indicate that while the maternal illnesses we 
evaluated in general are unlikely to contribute significantly to the development of ASD 
in offspring, some specific conditions, namely bacterial infections and asthma, may 
confer an increased risk. Additional studies are needed to assess the associations 
between maternal illnesses and ASD, particularly in large populations with the ability to 
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evaluate a large set of maternal conditions, their treatment and the interacting role of 
genetic factors. 
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Table 2.1. List of Autoimmune Diseases Considered in Analysis 
Addison disease Lichen sclerosus 
Alopecia areata Mixed Connective Tissue Disease 
Amyotrophic lateral sclerosis Multiple sclerosis 
Anemia autoimmunhemolytic; Myasthenia gravis 
Anemia pernicious Palsies 
Ankylosing spondylitis (Morbus Bechterew) Pemphigoid 
Anti phospholipid syndrome Pemphigus vulgaris 
Arteriitis temporalis and Takayasu's disease Polyarteriitis nodosa, Churg-Strauss and Kawasaki 
Autoimmune hepatitis Polymyalgia rheumatica 
Behcet's disease Polyneuritis, Polyneuropathy; 
Coeliac disease Psoriasis 
Dermatitis herpetiformis Reiter's disease 
Dermatomyositis and Polymyositis Rheumatoid Arthritis 
Diabetes Sarcoidosis 
Graves disease (Morbus Basedow) Scleroderma and CREST Syndrom 
Guillain -Barre Syndrome Sjogren Syndrom 
Hashimoto Thyroiditis Still's disease 
Henoch-Schoenlein Purpura Systemic lupus erythematosus 
Hyperthyroidism Thrombocytopenic purpura (Morbus Werlhof) 
Hypothyroidism Transverse myelitis 
lgA nephropathy Vitiligo 
Inflammatory bowel disease Wegener granulomatosis 
Table 2.2. Distributions of selected child and maternal characteristics among ASD case and non-ASD control subjects, GPRD 
singleton live births 1993-2008 
AAyASD Autistic Disorder Asperger's Other ASD 3 Controls 
(N=2207) (n=1548) Disorder (n=583) (n=76) (N=8815) 
n (%) n (%) n (%) n (%) n (%) 
Child Sex 
rvlale 1821 (82.5) 1260 (81.4) 501 (85.9) 60 (78.9) 7272 (82.5) 
Female 386 (17.5) 288 (18.6) 82 (14.1) 16(21 .1) 1543 (17.5) 
Mate rna I Age 
<20 years 111 (5.0) 71 (4.6) 37 (6.3) 3 (3.9) 522 (5.9) 
20-24 years 364 (16.5) 255 (16.5) 93 (16.0) 16 (21 .1) 1456 (16.5) 
25-29 years 601 (27.2) 419 (27.1) 166 (28.5) 16 (21.1) 2619 (29.7) 
30-34 years 723 (32.8) 501 (32.4) 191 (32.8) 31 (40.8) 2832 (32.1) 
35+ years 408 (18.5) 302 (19.5) 96 (16.5) 10 (13.2) 1386 (15.7) 
Maternal BMI 
w Underweight (<18.5 kg/m2 ) 71 (3.2) 46 (3.0) 22 (3.8) 3 (3.9) 313 (3.6) 
~ 
Normal weight (18.5-24.9 kg/m 2 ) 989 (44.8) 689 (44.5) 265 (45.5) 35(46.1) 4224 (47.9) 
Overweight (25-29.9 kg/m2 ) 389 (17.6) 176 (11.4) 100 (17.2) 13 (17.1) 1491 (16.9) 
Obese (30+ kg/m 2) 265 (12.0) 192 (12.4) 62 (10.6) 11 (14.5) 773 (8.8) 
Missing 493 (22.3) 345 (22.3) 134 (23.0) 14 (18.4) 2014 (22.8) 
Maternal Smoking 
Current 206 (9.3) 146 (9.4) 54 (9.3) 6 (7.9) 737 (8.4) 
Past 558 (25.3) 396 (25.6) 142 (24.4) 20 (26.3) 2179 (24.7) 
Never 1443 (65.4) 1006 (65.0) 387 (66.4) 50 (65.8) 5896 (66.9) 
Mssing 0 (0) 0 (0) 0 (0) 0 (0) 3 (0) 
Maternal Depression 
Yes 392 (17.8) 271 (17.5) 108 (18.5) 13 (17.1) 1150(13.0) 
No 1815 (82.2) 1277 (82.5) 475 (81.5) 63 (82.9) 7665 (87.0) 
Table 2.2. (continued) Distributions of selected child and maternal characteristics among ASD case and non-ASD control subjects, 
GPRD singleton live births 1993-2008 
AnyASD Autistic Disorder Asperger's Other ASDa Controls 
(N=2207) (n=1548) Disorder (n=583) (n=76) (N=8815) 
n (%) n (%) n (%) n (%) n (%) 
Maternal Drug Abuse 
Yes 17 (0.8) 15(1.0) 2 (0.3) 0 (0) 44 (0.5) 
No 2190 (99.2) 1533 (99.0) 581 (99.7) 76 (100) 8771 (99.5) 
Maternal Alcoholism 
Yes 40 (1.8) 32 (2.1) 7 (1.2) 1 ( 1.3) 170(1.9) 
No 2167 (98.2) 1516 (97.9) 576 (98.8) 75 (98.7) 8645 (98.1) 
Antenatal Folic Acid Prescriptions 
Yes 778 (35.3) 559 (36.1) 198 (34.0) 21 (27.6) 3123 (35.4) 
No 1429 (64.7) 989 (63.9) 385 (66.0) 55 (72.4) 5692 (64.6) 
w Autoimmune Disease Medicationsb 
N 
Prepregnancy 
Yes 329 (14.9) 241 (15.6) 79 (13.6) 9 (11.8) 1376 (15.6) 
No 1878(85.1) 1307 (84.4) 504 (86.4) 67 (88.2) 7439 (84.4) 
1st trimester 
Yes 34 (1 .5) 16 (1) 7 (1 .2) 1 ( 1.3) 75 (0.9) 
No 2183 (98.9) 1532 (99) 576 (98.8) 75 (98.7) 8740 (99.1) 
2nd trimester 
Yes 32 (1.4) 26 (1.7) 5 (0.9) 1 ( 1.3) 107 (1.2) 
No 2175 (98.6) 1522 (98.3) 578 (99.1) 75 (98.7) 8708 (98.8) 
3rd trimester 
Yes 38 (1 .7) 26 (1 .7) 12(2.1) 0 (0) 126 (1 .4) 
No 2169 (98.3) 1522 (98.3) 571 (97.9) 76 (100) 8689 (98.6) 
Table 2.2. (continued) Distributions of selected child and maternal characteristics among ASD case and non-ASD control subjects, 
GPRD singleton live births 1993-2008 
/VlyASD Autistic Disorder Asperger's Other AS08 Controls 
(N=2207) (n=1548) Disorder (n=583) (n=76) (N=8815) 
n (%) n (%) n (%) n (%) n (%) 
Asthma Medications 
Prepregnancy 
Yes 97(4.4) 81 (5.2) 15 (2.6) 1 ( 1.3) 372 (4.2) 
No 2110 (95.6) 1467 (94.8) 568 (97.4) 75 (98.7) 8443 (95.8) 
1st trimester 
Yes 19 (0.9) 15(1.0) 4 (0.7) 0 (0) 87 (1.0) 
No 2188(99.1) 1533 (99) 579 (99.3) 76(100) 8728 (99.0) 
2nd trimester 
Yes 15(0.7) 12 (0.8) 3 (0.5) 0 (0) 60 (0.7) 
No 2192 (99.3) 1536 (99.2) 580 (99.5) 76(100) 8755 (99.3) 
w 3rd trimester 
w Yes 11 (0.5) 8 (0.5) 3 (0.5) 0 (0) 34(0.4) 
No 2196 (99.5) 1540 (99.5) 580 (99.5) 76 (100) 8781 (99.6) 
AAtenatal Visits (records), number 
less than 10 272 (12.3) 186 (12.0) 78 (13.4) 8 (10.5) 1184 (13.4) 
10 or more 1935 (87.7) 1362 (88.0) 505 (86.6) 68 (89.5) 7631 (86.6) 
/Vltenatal Prescriptions, number 
0 prescription 309 (14.0) 220 (14.2) 78 (13.4) 11 (14.5) 1355 (15.4) 
1-5 prescriptions 547 (24.8) 381 (24.6) 148 (25.4) 15 (19.7) 2270 (25.8) 
6-10 prescriptions 457 (20.7) 314 (20.3) 123 (21 .1) 20 (26.3) 1995 (22.6) 
more than 10 prescriptions 894 (40.5) 633 (40.9) 234 (40.1) 27 (35.5) 3195 (36.2) 
aincludes subjects diagnosed with pervasive development disorder-not otherwise specified and those classified more generally as having an 
autistic spectrum disorder; bprescription medications commonly prescribed for autoimmune disease including immunosupressants, 
antimalarials , immunomodulators, systemic glucocorticoids, topical corticosteroids, and biologics; ASD=autism spectrum disorder; BMI=body 
mass index 
ASD=autism spectrum disorder; BMI=body mass index 
Table 2.3. Distributions of selected child and maternal characteristics by status of maternal infection, 
asthma, and autoimmune disease among 8816 non-ASD control subjects, GPRD singleton live births 
1993-2008 
Any lnfectiona Any Asthmab Any Autoimmune No lllnessc 
(n=3367) (n=1248) Diseaseb (n=744) (n=4431) 
n (%} n ~%) n (%) n (%) 
Child Sex 
Male 2760 (82.0) 1021 (81.8) 609 (81.9) 3670 (82.8) 
Female 607 (18.0) 227 (18.2) 135 (18.1) 761 (17.2) 
Maternal Age 
<20 years 220 (6.5) 113(9.1) 32 (4.3) 226 (5.1) 
20-24 years 600 (17.8) 273 (21.9) 101 (13.6) 676 (15.3) 
25-29 years 1006 (29.9) 385 (30.8) 219 (29.4) 1303 (29.4) 
w 30-34 years 1063 (31.6) 337 (27.0) 250 (33.6) 1482 (33.4) 
.j:::. 
35+ 478 (14.2) 140(11.2) 142(19.1) 744 (16.8) 
Maternal BMI, Mean {sd) 
Underweight (<18.5 kg/m2) 130 (3.9) 49 (3.9) 20 (2.7) 147 (3.3) 
Normal weight (18.5-24.9 kg/m2) 1630 (48.4) 557 (44.6) 341 (45.8) 2138 (48.3) 
Overweight (25-29.9 kg/m2) 580 (17.2) 234 (18.8) 139 (18.7) 724 (16.3) 
Obese (30+ kg/m2) 319 (9.5) 163(13.1) 103 (13.8) 326 (7.4) 
Missing 708 (21) 245 (19.6) 141 (19.0) 1096 (24.7) 
Maternal Smoking 
Current 275 (8.2) 133 (10.7) 79 (10.6) 348 (7.9) 
Past 908 (27.0) 354 (28.4) 217 (29.2) 995 (22.5) 
Never 2184 (64.9) 761 (61.0) 448 (60.2) 3085 (69.6) 
Missing 0 (0) 0 (0) 0 (0) 3 (0.1) 
Table 2.3. (continued) Distributions of selected child and maternal characteristics by status of 
maternal infection, asthma, and autoimmune disease among 8816 non-ASD control subjects, GPRD 
singleton live births 1993-2008 
Any lnfectiona Any Asthmab Any Autoimmune No lllnessc 
(n=3367) (n=1248) Diseaseb (n=744) (n=4431) 
n (%) n (%) n (%) n (%) 
Maternal Depression 
Yes 549 (16.3) 212 (17.0) 133 (17.9) 458 (10.3) 
No 2818 (83.7) 1036 (83.0) 611 (82.1) 3973 (89.7) 
Maternal Drug Abuse 
Yes 23 (0.7) 14(1.1) 6 (0.8) 17 (0.4) 
No 3344 (99.3) 1234 (98.9) 738 (99.2) 4414 (99.6) 
Maternal Alcoholism 
w Yes 71 (2.1) 25 (2.0) 21 (2.8) 75 (1.7) U"1 
No 3296 (97.9) 1223 (98.0) 723 (97.2) 4356 (98.3) 
Antenatal Folic Acid Prescriptions 
Yes 1395(41.4) 447 (35.8) 289 (38.8) 1399 (31.6) 
No 1972 (58.6) 801 (64.2) 455 (61.2) 3032 (68.4) 
Autoimmune disease medicationsd 
Prepregnancy 
Yes 659 (19.6) 253 (20.3) 203 (27.3) 519(11.7) 
No 2708 (80.4) 995 (79.7) 541 (72.7) 3912 (88.3) 
1 st trimester 
Yes 39 (1.2) 18(1.4) 16 (2.2) 24 (0.5) 
No 3328 (98.8) 1230 (98.6) 728 (97.8) 4407 (99.5) 
Table 2.3. (continued) Distributions of selected child and maternal characteristics by status of 
maternal infection, asthma, and autoimmune disease among 8816 non-ASD control subjects, GPRD 
singleton live births 1993-2008 
Any lnfection 3 Any Asthmab Any Autoimmune No lllnessc 
(n=3367) (n=1248) Diseaseb (n=744) (n=4431) 
n (%) n (%) n ~%~ n (%) 
Autoimmune disease medicationsd 
2nd trimester 
Yes 60 (1.8) 27 (2.2) 18(2.4) 31 (0.7) 
No 3307 (98.2) 1221 (97.8) 726 (97.6) 4400 (99.3) 
3rd trimester 
Yes 72 (2.1) 25 (2.0) 27 (3.6) 35 (0.8) 
No 3295 (97.9) 1223 (98.0) 717 (96.4) 4396 (99.2) 
w Asthma medications 0"1 
Prepregnancy 
Yes 146 (4.3) 139(11.1) 28 (3.8) 134 (3.0) 
No 3221 (95.7) 1109 (88.9) 716 (96.2) 4297 (97) 
1st trimester 
Yes 39 (1.2) 34 (2.7) 12 (1.6) 27 (0.6) 
No 3328 (98.8) 1214 (97.3) 732 (98.4) 4404 (99.4) 
2nd trimester 
Yes 24 (0.7) 28 (2.2) 8 (1 .1) 19(0.4) 
No 3343 (99.3) 1220 (97.8) 736 (98.9) 4412 (99.6) 
3rd trimester 
Yes 16 (0.5) 13(1.0) 4 (0.5) 12 (0.3) 
No 3351 (99.5) 1235 (99.0) 740 (99.5) 4419 (99.7) 
w 
"'--
Table 2.3. (continued) Distributions of selected child and maternal characteristics by status of 
maternal infection, asthma, and autoimmune disease among 8816 non-ASD control subjects, GPRD 
singleton live births 1993-2008 
Any lnfectiona Any Asthmab Any Autoimmune No lllnessc 
(n=3367) (n=1248) Diseaseb (n=744) (n=4431) 
n (%) n ~%) n (%) n (%) 
Antenatal visit (records), number 
less than 10 102 (3.0 144(11.5) 64 (8.6) 903 (20.4) 
10 or more 3265 (97.0) 1104 (88.5) 680 (91.4) 3528 (79.6) 
Antenatal prescriptions, number 
0 prescriptions 147 (4.4) 107 (8.6) 82 (11.0) 1045 (23.6) 
1-5 prescriptions 646 (19.2) 222 (17.8) 135 (18.1) 1382 (31.2) 
06-1 0 prescriptions 809 (24.0) 214 (17.1) 145 (19.5) 990 (22.3) 
more than 10 prescriptions 1765 (52.4) 705 (56.5) 382 (51.3) 1014 (22.9) 
3 SUbjects with a diagnosis for an infection anytime from 3 months before the start of pregnancy to the date of delivery 
for the study pregnancy; bsubjects with an asthma or autoimmune disease diagnosis anytime from the start of the 
GPRD record through one year after the date of delivery for the study pregnancy; csubjects with no indication of 
infection in the 3 months before through the end of the study pregnancy who also have no documented history of 
asthma or autoimmune disease from the start of the GPRD record through one year after the date of delivery for the 
study pregnancy; dprescription medications commonly prescribed for autoimmune disease including 
immunosupressants, antimalarials, immunomodulators, systemic glucocorticoids, topical corticosteroids, and 
biologics; ASD=autistic spectrum disorders; BMI=body mass index 
Table 2.4. Frequency of periconceptional infection in mothers of children with an autistic spectrum disorder and mothers 
of control children, GPRD singleton live births 1993-2008 
Any ASD Autistic Disorder Asperger Disorder Other ASD 3 
(n=2207) (n=1548) (n=583) (n=76) 
Control 
(n-8815) 
n (%) n (%) n (%) n (%) ____ _D (%) 
Any infection 863 (39.1) 594 (38.4) 240 (41 .2) 29 (38.2) 3367 (38.2) 
Bacterial infection 300 (13.6) 200 (12.9) 91 (15.6) 9 (11.8) 1155 (13.1) 
Viral infection 499 (22.6) 333 (21 .5) 148 (25.4) 18 (23.7) 2000 (22.7) 
Infectious enteritis 17 (0.8) 9 (0.6) 8 (1.4) 0 (0) 80 (0.9) 
Repiratoryinfection 415(18.8) 275(17.8) 128(22.0) 12(15.8) 1625(18.4) 
Skin infection 72 (3.3) 47 (3.0) 23 (3.9) 2 (2.6) 246 (2.8) 
Urinary tract infection 207 (9.4) 139 (9.0) 61 (10.5) 7 (9.2) 761 (8.6) 
Genital infection (non-STI) 40 (1.8) 29 (1.9) 11 (1.9) 0 (0) 166 (1.9) 
Sexually transmitted infection 16 (0.7) 9 (0.6) 6 (1.0) 1 (1.3) 81 (0.9) 
~ 8 includes subjects diagnosed with pervasive development disorder-not otherwise specified and those classified more generally as having an 
autistic spectrum disorder; ASD=autism spectrum disorder; STI=sexually transmitted infection 
w 
\.0 
Table 2.5. Conditional unadjusted and multivariable adjusted odds ratios (OR) and associated 95% confidence intervals (CI) for autism 
spectrum disorders in relation to maternal infection, GPRD singleton live births 1993-2008 
Any ASD Autistic Disorder Asperger's Disorder 
1 OR unadjusted 2 OR adjusted 1 OR unadjusted 2 OR adjusted OR 1 unadjusted 2 OR adjusted 
(95% Cl) (95% Cl) (95% Cl) (95% Cl) (95% Cl) (95% Cl) 
Any infection 1.07 (0.96, 1.19) 1.10 (0.95, 1.28) 1.04 (0.91 , 1.19) 1.01 (0.86, 1.19) 1.13 (0.91 , 1.39) 1.14 (0.88 , 1.48) 
Bacterial infection 1.04 (0.88, 1.23) 0.91 (0.72, 1.15) 0.98 (0.81, 1.21) 0.95 (0.75, 1.22) 1.18 (0.87, 1.61) 0.95 (0.64 , 1.41) 
Viral infection 1.03 (0 .90, 1.18) 0.97 (0 .80, 1.16) 0.96 (0 .82, 1.13) 0.91 (0 .75, 1.1 0) 1.23 (0 .95, 1.59) 1.32 (0.96 , 1.81) 
Infectious enteritus 1.05 (0.56, 1.97) 1.11 (0.51, 2.40) 0.81 (0.36, 1.85) 0.67 (0.22, 2.01) 3.06 (0.84, 11 .2) 3.44 (0.92, 12.8) 
Respiratoryinfection 1.07(0.92, 1.23) 0.97(0.81 , 1.15) 1.00(0.84, 1.19) 0.89(0.72,1 .10) 1.29(0.98, 1.71) 1.31(0.93,1.85) 
Skin infection 1.14 (0.80, 1.60) 1.05 (0 .83 , 1.32) 0.91 (0.60, 1.39) 0.87 (0.51, 1.4 7) 2.32 (1.17, 4.63) 2.21 (0.83 , 5.90) 
Urinary tract infection 1.14 (0.93 , 1.38) 1.07 (0.84, 1.36) 1.11 (0.88, 1.41) 1.12 (0.84 , 1.51) 1.18 (0.82, 1.70) 0.95 (0.60 , 1.51) 
Genital infection (not including STI's) 0.69 (0.40, 1.19) 0.69 (0.40 , 1.20) 1.13 (0.68, 1.88) 0.92 (0.47, 1.80) 0.53 (0.19, 1.51) 0.47 (0.16 , 1.36) 
Sexually transmitted infection 0.85 (0.41, 1.74) 0.94 (0.38, 2.35) 0.73 (0.29 , 1.80) 0.80 (0.25, 2.53) 1.32 (0.38, 4.64) 1.43 (0.27, 7 .39) 
1unadjusted models control for matching factors (child birth year, sex, and general practice) only; 2fully adjusted model controls for maternal age (continuous), 
maternal pre-pregnancy body mass index, depression, smoking status , alcoholism, drug abuse, and antenatal folic acid prescriptions ; ASD=autism spectrum 
disorder; STI=sexually transmitted infection 
Table 2.6. Conditional multivariable adjusted odds ratios (OR) and associated 95% 
confidence intervals (CI) for autism spectrum disorders in relation to maternal infection by 
trimester, GPRD singleton live births 1993-2008 
Any infection 
Bacterial infection 
Viral infection 
Infectious enteritus 
Respiratory infection 
Skin infection 
Urinary tract infection 
Genital infection 
Sexuall:t transmitted infection 
Any infection 
Bacterial infection 
Viral infection 
Prepregnancy 
Exposed ORadjusted 1 
Cases, Controls (95%CI) 
206, 776 0.94 (0.76, 1.17) 
70, 207 1.16 (0.80, 1.68) 
112, 449 0.89 (0.67, 1.19) 
4, 14 NE 
100,376 0.89 (0.66, 1.20) 
17, 56 1.04 (0.48, 2.25) 
38, 103 1.64 (0.97, 2.75) 
16, 45 0.77 (0.35, 1.68) 
2, 11 NE 
Trimester2 
Exposed 
Cases, Controls 
263, 1118 
77, 324 
135, 552 
1 ORadjusted 
(95%CI) 
0.89 (0.73, 1.08) 
0.87 (0.62, 1.22) 
0.91 (0.70, 1.18) 
Trimester 1 
Exposed ORadjusted 1 
Cases, Controls (95%CI) 
219, 800 1.07 (0.86, 1.33) 
61 ' 239 1.05 (0.69, 1.59) 
119,446 0.99 (0.74, 1.31) 
4, 15 NE 
92, 341 1.02 (0.75, 1.40) 
17, 57 1.48 (0.61 ' 3.56) 
39, 153 0.98 (0.60, 1.63) 
6, 27 0.63 (0 .16, 2.41) 
1' 18 NE 
Trimester3 
Exposed 
Cases, Controls 
297, 1051 
80, 307 
127, 446 
ORadjusted 1 
(95%CI) 
1.10 (0.91 ' 1.33) 
0.93 (0.66, 1.30) 
1.16 (0.88, 1.53) 
Infectious enteritus 2, 20 NE 5, 11 1.79 (0.39, 8.39) 
Respiratory infection 104, 429 0.84 (0.62, 1.12) 106, 367 1.18 (0 .86, 1.61) 
Skin infection 9, 49 0.57 (0.22, 1.47) 20, 44 1.38 (0.66, 2.90) 
Urinary tract infection 63, 216 1.09 (0.75, 1.59) 55 , 221 0.87 (0.59, 1.30) 
Genital infection 2, 40 NE 7, 30 0.87 (0.29, 2.65) 
Sexuallytransmittedinfection 7, 22 2.77(0.51 , 15.2) 3, 19 NE 
1fully adjusted model controls for maternal age (continuous), matemal pre-pregnancy body mass index, 
depression, smoking status, alcoholism, drug abuse, and antenatal folic acid prescriptions; NE=not 
estimated, too few exposed cases 
40 
Table 2.7. Conditional multivariable adjusted odds ratios (OR) and associated 95% confidence intervals (CI) for autism spectrum disorders in 
relation to maternal infection- restricted to individuals with a GP-recorded pregnancy start date, GPRD singleton live births 1993-2008 
Any ASD Autistic Disorder Asperger's Disorder 
Exposed 1 OR adjusted Exposed 1 OR adjusted Exposed 1 OR adjusted 
Cases, Controls (95% Cl) Cases, Controls (95% Cl) Cases, Controls (95% Cl) 
Any infection 471,1706 1.15 (0.95, 1.39) 342,1706 1.21 (0.97 , 1.52) 116, 1706 1.08 (0.73, 1.59) 
Bacterial infection 180,559 1.47 (1.10, 1.97) 129, 5599 1.48 (1.05, 2.1 0) 46, 559 1.53 (0.82 , 2.87) 
Viral infection 261 , 1023 1.00 (0.78, 1.27) 185, 1023 0.99 (0.75, 1.31) 69, 1023 1.17 (0.70, 1.97) 
Infectious enteritus 9, 44 1.05 (0.38, 2.94) 4,44 NE 5, 44 3.91 (0.76, 20.23) 
Respiratory infection 220,860 0.95 (0.73, 1.22) 156, 860 0.94 (0.70, 1.28) 60, 860 1.08 (0.16 , 3.13) 
Skin infection 41 , 134 1.61 (0.90, 2.93) 31 ' 134 1.55 (0.78, 3.1 0) 10, 134 3.29 (0.72, 15.1) 
Urinary tract infection 127,365 1.62(1 .14, 2.29) 91 ' 365 1.68 (1 .12, 2.54) 31,365 1.41 (0.67, 2.99) 
Genital infection 23 , 75 1.65 (0 .73, 3.71) 17, 75 2.79 (0.92, 8.49) 6,75 0.87 (0.21' 3.51) 
Sexually transmitted infection 6, 38 1.33 (0.30, 5.81) 3,38 NE 3, 38 NE 
e. 1fully adjusted model controls for maternal age (continuous) , maternal pre-pregnancy body mass index, depression, smoking status, alcoholism, drug abuse, and 
antenatal folic acid prescriptions; ASD=autism spectrum disorder; NE=not estimated, too few exposed cases 
Table 2.8. Conditional multivariable adjusted odds ratios (OR) and associated 95% confidence 
intervals (CI) for autism spectrum disorders in relation to maternal infection by trimester- restricted 
to individuals with a GP-recorded pregnancy start date, GPRD singleton live births 1993-2008 
Prepregnancy Trimester 1 
Exposed 1 OR adjusted Exposed 1 OR adjusted 
Cases , Controls (95%CI) Cases, Controls (95%CI) 
Any infection 140, 473 1.24 (0 .89, 1.72) 146, 505 1.20 (0.87 ' 1.65) 
Bacterial infection 51 , 125 1.75 (0.99, 3.11) 44, 144 1.87 (1.03, 3.40) 
Viral infection 72,275 1.13 (0.74, 1.74) 76, 292 1.14 (0.75, 1.74) 
Infectious enteritus 2, 10 NE 2, 14 NE 
Respiratory infection 65 , 229 1.16 (0.73, 1.85) 63, 234 1.12 (0.71, 1.77) 
Skin infection 11 , 33 1.59 (0.48, 5.20) 12, 37 7.01 (1.28, 38 .5) 
Urinary tract infection 28, 66 2.58 (1 .14, 5.84) 28, 91 1.30 (0.64, 2.68) 
Genital infection (not including STI's) 13,23 1.50 (0 .52, 4.38) 4, 15 NE 
Sexually transmitted infection 1, 9 NE 0, 11 NE 
Trimester2 Trimester3 
Exposed 1 OR adjusted Exposed 1 OR adjusted 
Cases, Controls (95%CI) Cases , Controls (95%CI) 
Any infection 179,698 0.97 (0.73, 1.29) 208, 683 1.30 (1.00, 1.69) 
Bacterial infection 56, 187 1.09 (0.67,1.79) 62, 187 1.76 (1.09, 2.83) 
Viral infection 81 , 349 0.83 (0.54, 1.26) 84, 305 1.23 (0.82 , 1.85) 
Infectious enteritus 1' 12 NE 4, 9 NE 
Respiratory infection 67, 284 0.51 (0.04, 6.13) 67,257 1.09 (0.69, 1.71) 
Skin infection 10, 41 0.69 (0.24, 2.03) 15, 31 2.64 (0.98, 7.1 0) 
Urinary tract infection 44, 124 1.40 (0.79, 2.47) 41' 130 1.68 (0.95 , 2.98) 
Genital infection (not including STrs) 1' 17 NE 6, 21 1.23 (0.23 , 6.57) 
Sexuall~ transmitted infection 2,7 2.77 (0.51' 15.2) 3, 13 NE 
1fully adjusted model controls for maternal age (continuous), maternal pre-pregnancy body mass index, depression, 
smoking status, alcoholism, drug abuse, and antenatal folic acid prescriptions; NE=not estimated, too few exposed 
cases; STI=sexually transmitted infection 
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Table 2.9. Frequency of autoimmune diseases and asthma in mothers of children with an autism 
spectrum disorder and mothers of control children, GPRD singleton live births 1993-2008 
Autistic Asperger 
AnyASD Disorder Disorder OtherASD Controls 
(n=2207) (n=1548) (n=583) (n=76) (n=8815) 
n (%) n (%) n (%) n (%) n (%) 
Any Asthma 353 (16.0) 239 (15.4) 103 (17.7) 11 (14.5) 1248 (14.2) 
Any Autoimmune Disease 189 (8.6) 132 (8.5) 54 (9.3) 3 (3.9) 744(8.4) 
Addison Disease 0 (0) 0 (0) 0 (0) 0 (0) 1 (0) 
Alopecia Areata 33 (1.5) 25 (1.6) 8 (1.4) 0 (0) 108 (1.2) 
Autoimmune anemia 1 (0) 1 (0.1) 0 (0) 0 (0) 2 (0) 
Ankylosing Spondylitis 5 (0.2) 3 (0.2) 2 (0.3) 0 (0) 12 (0.1) 
Antiphospholipid Syndrome 2 (0.1) 1 (0.1) 1 (0.2) 0 (0) 2 (0) 
Behcets Disease 0 (0) 0 (0) 0 (0) 0 (0) 1 (0) 
Coeliac Disease 2 (0.1) 1 (0.1) 1 (0.2) 0 (0) 14 (0.2) 
Dermatitis Herpetiformis 0 (0) 0 (0) 0 (0) 0 (0) 5 (0.1) 
Dermatomyositis or Polymyositis 1 (0) 1 (0.1) 0 (0) 0 (0) 0 (0) 
Diabetes 19(0.9) 11 (0.7) 6 (1.0) 2 (2.6) 39 (0 .4) 
Graves Disease 3 (0.1) 2 (0.1) 1 (0.2) 0 (0) 9 (0.1) 
Guillain Barre Syndrome 1 (0) 0 (0) 0 (0) 1 (1.3) 3 (0) 
Hashimoto Thyroiditis 3 (0.1) 1 (0 .1) 2 (0.3) 0 (0) 6 (0.1) 
Henoch Schoenlein Purpura 3 (0.1) 3 (0.2) 0 (0) 0 (0) 18 (0.2) 
Hyperthyroidism 8 (0.4) 6 (0.4) 2 (0.3) 0 (0) 22 (0.2) 
Hypothyroidism 25 (1.1) 21(1 .4) 4 (0 .7) 0 (0) 81 (0 .9) 
Inflammatory Bowel Disease 12 (0.5) 9 (0.6) 3 (0 .5) 0 (0) 46 (0.5) 
Lichen Sclerosus 1 (0) 1 (0.1) 0 (0) 0 (0) 5 (0.1) 
Multiple Sclerosis 1 (0) 1 (0.1) 0 (0) 0 (0) 10 (0.1) 
Myasthenia Gravis 0 (0) 0 (0) 0 (0) 0 (0) 1 (0) 
Palsies 13 (0.6) 8 (0.5) 4 (0 .7) 1 (1.3) 64 (0.7) 
Pemphigus Vulgaris 0 (0) 0 (0) 0 (0) 0 (0) 2 (0) 
Psoriasis 49 (2.2) 38 (2.5) 11 (1.9) 0 (0) 246 (2.8) 
Reiters Disease 1 (0) 1 (0.1) 0 (0) 0 (0) 4 (0) 
Rheumatoid Arthritis 10(0.5) 6 (0.4) 4 (0.7) 0 (0) 48 (0 .5) 
Sarcoidosis 4 (0.2) 2 (0.1) 2 (0.3) 0 (0) 6 (0.1) 
Scleroderma and CREST Syndrome 0 (0) 0 (0) 0 (0) 0 (0) 5 (0 .1) 
Sjogren Syndrome 1 (0) 0 (0) 1 (0.2) 0 (0) 0 (0) 
Stills Disease 0 (0) 0 (0) 0 (0) 0 (0) 3 (0) 
Systemic Lupus Erythematosus 5 (0.2) 2 (0.1) 3 (0.5) 0 (0) 4 (0) 
Thrombocytopenic Purpura 2 (0.1) 2 (0.1) 0 (0) 0 (0) 12 (0.1) 
Transverse Myelitis 2 (0.1) 1 (0.1) 1 (0.2) 0 (0) 3 (0) 
Vitiligo 5 (0.2) 3 (0.2) 2 (0.3) 0 (0) 16 (0 .2) 
We9ener Granulomatosis 0 ~0~ 0 ~0~ 0 (0~ 0 ~0~ 1 ~0~ 
Specific autoimmune diseases are presented if at least 1 case mother or at least one control mother was 
affected; ASD=autism spectrum disorder; CREST= calcinosis , Raynaud phenomenon, esophageal dysmotility, 
sclerodactyly, and telangiectasia 
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Table 2.10. Conditional unadjusted and multivariable adjusted odds ratios (OR) and associatioed 95% confidence intervals (CI) for 
autism spectrum disorders in relation to maternal asthma and autoimmune disease, GPRD singleton live births 1993-2008 
Any ASD Autistic Disorder Asperger's Disorder 
(N=2207) (n=1548) (n=583) 
1 OR unadjusted OR2 adjusted 1 OR unadjusted 2 OR adjusted OR 1 unadjusted 2 OR adjusted 
(95% Cl) (95% Cl) (95% Cl) (95% Cl) (95% Cl) (95% Cl) 
Asthma 1.29 (1 .08, 1.54) 1.27 (1 .06, 1.53) 1.21 (1.01 , 1.45) 1.29 (1 .03, 1.61) 1.28 (0.91 , 1.78) 1.24 (0.88, 1.77} 
Any Autoimmune Disease 0.96 (0. 75, 1.22) 0.89 (0. 70, 1.15) 0.84 (0.62, 1.12) 0.76 (0.56, 1.03) 1.50 (0 .93, 2.41) 1.54 (0.93, 2.53) 
Specific autoimmune diseases 
Alopecia Areata 1.27(0.75,2.16) 1.30(0.75,2.23) 1.13(0.62,2.07) 1.13(0.61,2.13) 1.49(0.93,2.41) 1.98(0.63,6.24) 
Anky1osing Spondylitis 1.96 (0.42, 9.09) NE NE NE NE NE 
Diabetes 1.69 (0.85, 3.37) 1.48 (0.73, 2.97) 1.26 (0.55, 2.88) 1.01 (0.43, 2.37) NE NE 
Hyperthyroidism 1.32 (0.42, 4.13) 2.17 (0.60, 7.90) 1.50 (0.32, 7.03) 1.83 (0.32, 8.99) NE NE 
Hypothyroidism 1.09 (0.59, 2.00) 0.94 (0.50, 7 .76) 1.09 (0.53, 2.20) 0.89 (0.43, 1.85) 1.24 (0.36, 4.28) NE 
Inflammatory Bowel Disease 0.96 (0.40, 2.32) 0.89 (0.36, 2.19) 0.86 (0.28, 2.62) 0.66 (0.21, 2.08) NE NE 
Palsies 0.50 (0.20, 1.25) 0.46 (0.18, 1.16) 0.41 (0.14, 1.23) 0.36 (0.12, 1.11) 1.07 (0.19, 6.02) NE 
Psoriasis 0.73 (0.46, 1.17) 0.69 (0.43, 1.10) 0.88 (0.51 , 1.52) 0.82 (0.47, 1.44) 0.54 (0.21, 1.38) 0.54 (0.21 , 1.41) 
Rheumatoid Arthritis 0.94 (0.36, 2.43) 0.87 (0.33, 2.28) 0.85 (0.25, 2.86) NE 1.11 (0.23, 5.17) NE 
Vitiligo 0.57 (0 .15, 2.14) NE NE NE NE NE 
1unadjusted models control for matching factors (child birth year, sex, and general practice) only; 2fully adjusted model controls for maternal age 
(continuous), maternal pre-pregnancy body mass index, depression, smoking status, alcoholism , drug abuse, antenatal fol ic acid prescriptions and 
autoimmune disease medication prescriptions; ASD=autism spectrum disorder; NE=not estimated; fewer than 5 exposed cases or 5 exposed controls 
Table 2.11. Conditional multivariable adjusted odds ratios (OR) and associated 
95% confidence intervals (CI) for autistic spectrum disorders in relation to 
maternal asthma and autoimmune disease by period of diagnosis, GPRD 
singleton live births 1993-2008 
Asthma 
History 
Trimester 1 
Trimester 2 
Trimester 3 
Postdelivery 
Autoimmune Disease 
Exposed 
Cases, Controls 
269,927 
3,15 
4,12 
2, 13 
3,36 
1 OR adjusted 
(95% Cl) 
1.34 (1.11, 1.62) 
NE 
NE 
NE 
NE 
History 110, 506 0.79 (0.60, 1.06) 
Trimester 1 3, 9 NE 
Trimester2 5,10 1.92 (0.65, 5.69) 
Trimester 3 2, 12 NE 
Postdelivery 27, 75 1.40 (0.78, 2.48) 
1fully adjusted model controls for maternal age (continuous), maternal pre-pregnancy body 
mass index, depression, smoking status, alcoholism, drug abuse, antenatal folic acid 
prescriptions , and autoimmune disease medication use; ASD=autism spectrum disorder; 
NE=not estimated; fewer than 5 exposed cases or 5 exposed controls 
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Table 2.12. Conditional multivariable adjusted odds ratios (OR) 
and associated 95% confidence intervals (CI) for autism spectrum 
disorders in relation to maternal asthma and autoimmune disease 
-restricted pre-pregnancy window, GPRD singleton live births 
1993-2008 
Asthma 
Any Autoimmune Disease 
Specific autoimmune diseases 
Alopecia Areata 
Ankylosing Spondylitis 
Diabetes 
Hyperthyroidism 
Hypothyroidism 
Inflammatory Bowel Disease 
Palsies 
Psoriasis 
Rheumatoid Arthritis 
Vitiligo 
Any ASD (N=2207) 
Exposed 
Cases, Controls 
53,209 
61' 246 
13,48 
1' 5 
8,9 
5,11 
10,41 
6, 14 
2,26 
12,67 
3, 13 
3, 7 
1 OR adjusted 
(95% Cl) 
1.20 (0.81' 1.79) 
0.90 (0.62, 1.31) 
1.14 (0.54, 2.40) 
NE 
2.64 (0.78, 8.92) 
2.51 (0.39, 16.1) 
0.85 (0.33, 2.15) 
1.07 (0.27, 4.18) 
NE 
0.46 (0.19, 1.11) 
NE 
NE 
1fully adjusted model controls for maternal age (continuous), maternal pre-
pregnancy body mass index, depression, smoking status, alcoholism, drug 
abuse, antenatal folic acid prescriptions and autoimmune disease medication 
prescriptions; ASD=autism spectrum disorder; NE=not estimated; fewer than 
5 exposed cases or 5 exposed controls 
Restricted to include diagnoses with two years before pregnancy start 
through one year after delivery of study pregnancy 
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Table 2.13. Conditional unadjusted and multivariable adjusted odds ratios (OR) and associated 95% confidence intervals (CI) for 
autism spectrum disorders in relation to maternal asthma and autoimmune disease- restricted to individuals with a GP-recorded 
pregnancy start date , GPRD singleton live births 1993-2008 
Any ASD (N=2207) Autism (n=1548) Asperger's (n=583) 
Exposed Adjusted1 OR Exposed Adjusted 1 OR Exposed Adjusted1 OR 
Cases, Controls (95% Cl) Cases, Controls (95% Cl) Cases, Controls (95% Cl) 
Asthma 160, 564 1.35 (1 .04, 1.77} 112, 564 1.43 (1.03, 1.98} 46, 564 1.34 (0.81 ' 2.21} 
Any Autoimmune Disease 75, 331 0.76 (0.53, 1.1 0) 57, 331 0.68 (0.44, 1.06) 17, 331 1.03 (0.48, 2.20) 
Specific autoimmune diseases 
Alopecia Areata 12, 49 0.88 (0.38, 2.02) 10, 49 1.09 (0.42, 2.83) 2, 49 0.46 (0.07, 3.02) 
Ankylosing Spondylitis 1' 6 NE 1, 6 NE 0, 6 NE 
Diabetes 9, 18 1.86 (0.72, 4.81) 6, 18 1.15 (0.36, 3.64) 2, 18 NE 
Hyperthyroidism 5, 13 3.98 (0 .63, 25.2) 4, 13 NE 1' 13 NE 
Hypothyroidism 14, 32 1.15 (0.45, 2.99) 12, 32 1.21 (0.38, 3.84) 2, 32 2.08 (0.31 ' 13.82) 
Inflammatory Bowel Disease 5, 24 0.44 (0 .11 ' 1.75) 4,24 0.52 (0.12, 2.15) 1, 24 NE 
Palsies 3, 33 NE 2, 33 NE 1' 33 NE 
Psoriasis 21 , 101 0.77 (0 .38, 1.57) 16, 101 0.86 (0 .35, 2.12) 5, 101 0.63 (0.17, 2.30) 
Rheumatoid Arthritis 3, 21 NE 2,21 NE 1, 21 NE 
Vitiligo 4,8 NE 3,8 NE 1' 8 NE 
1fully adjusted model controls for maternal age (continuous), maternal pre-pregnancy body mass index, depression, smoking status, alcoholism , drug 
abuse, antenatal folic acid prescriptions and asthma medication prescriptions (asthma associations only) or autoimmune disease medication 
prescriptions (for till associations only); ASD=autism spectrum disorder; NE=not estimated; fewer than 5 exposed cases or 5 exposed controls 
3. THE ASSOCIATION BETWEEN MATERNAL PREPREGNANCY BODY MASS INDEX AND 
AUTISM SPECTRUM DISORDERS AMONG OFFSPRING: A CASE-CONTROL STUDY 
3.1. ABSTRACT 
Previous studies have attributed high maternal weight gain during pregnancy and pre-
pregnancy obesity to a higher risk for autism spectrum disorders (ASD). Maternal 
underweight was not previously explored with respect to ASD risk. We evaluated the 
association between maternal pre-pregnancy body mass index and ASD occurrence 
among singletons born into the General Practice Research Database from 1993 through 
2008. Case subjects were children with a diagnosis on the autism spectrum. Up to four 
control subjects were matched to each case subject on birth year, sex, and general 
practice. Non-linearity of the association between maternal BMI and ASD was assessed 
with restricted cubic splines. All study subjects were classified based on their mother's 
pre-pregnancy BMI as underweight, normal weight, overweight or obese using the WHO 
Classification Standard. Conditional logistic regression was used to calculate crude and 
multivariable adjusted odds ratios for the association between categorical BMI 
(reference=normal weight) and the occurrence of any ASD and specific ASD subtypes. 
The association between maternal BMI and ASD occurrence was non-linear and J-
shaped (p=0.003). The ORs for maternal underweight and obesity were 1.4 (95% Cl : 1.0, 
2.0) and 1.5 (95% Cl: 1.3, 1.9), respectively, and did not differ by ASD subtype. Results 
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suggest that extremes in maternal BMI may be associated with modest increases in the 
risk for ASD among offspring. 
3.2. INTRODUCTION 
The prevalence of ASD has increased dramatically over the past few decades, rising from 
less than 20 per 10,000 persons in the 1980's (1) to recent estimates as high as 1 per 88 
persons, and has consistently been found to be approximately 4 times higher in males 
than females (1, 2). While a true increase in prevalence cannot be ruled out, the 
increasing rate is considered in part to be a result of the changes in diagnostic criteria 
and greater overall awareness of the disorder (3). 
The prevalence of obesity has exhibited a temporal increase that parallels that of 
ASD. In the UK, nearly a quarter of the population is obese and about 16% of women 
are obese at the start of pregnancy, up from 9% in 1990 (4). Previous studies have 
attributed high maternal weight gain during pregnancy (5) and pre-pregnancy obesity 
(6, 7) to a higher risk for ASD. However, these studies have not distinguished between 
ASD subtypes and relied to some degree on retrospective self-report of maternal height 
and weight information. No study to date has explored ASD risk in relation to 
underweight. The current study evaluated the relationship between maternal pre-
pregnancy BMI measurements recorded prospectively within the UK-based General 
Practice Research Database and ASD occurrence among singletons born from 1993 
through 2008. 
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3.3. METHODS 
3.3.1. Data Source 
The UK General Practice (GPRD) is a primary care database containing anonymized 
records for nearly 4 million active patients (about 6% of the population of England, 
Northern Ireland, Scotland and Wales) from more than 450 selected general practices 
(8). These general practitioners have agreed to provide data for research purposes to 
the GPRD on an ongoing basis and received instruction on the standardized recording of 
medical information including the Read diagnosis coding system and multilex drug codes 
(9). Participating general practices not only record each episode of illness and medical 
diagnoses, but also clinical contacts, examination findings, therapeutic and 
administrative procedures, test results, drug prescriptions, and referrals to specialists 
and outpatient clinics with the associated diagnoses. Patients have both a unique 
individual identification code and a family code. A mother's records can be matched to 
offspring records based on family identification number, GP practice code, infant's birth 
year and mother's pregnancy outcome date (10, 11}. Additionally, the start of the first 
trimester of pregnancy can be identified in the majority of mother-offspring matched 
pregnancies, thus permitting the study of the effects of maternal pre-pregnancy 
exposures on the development of offspring (11). Validation studies have verified most of 
the diagnoses coded in the GPRD electronic record to be highly accurate (i.e., a median 
of 90% of diagnoses confirmed) when compared against GP questionnaire responses, 
hospital letters, and medical records held at the GP practice, with diagnoses of chronic 
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illness being somewhat more accurate than those of acute illness (8, 12-14). This study 
utilized data derived from the version of the General Practice Research Database (GPRD) 
maintained by the Boston Collaborative Drug Surveillance Program (13). 
3.3.2. Study Population 
All ASD cases and non-ASD controls were identified from a source population 
consisting of all singleton live births from 1993 through 2008 who were registered with 
the GPRD at birth and whose records were successfully matched to their mother with 
one or more years of recorded history in the database before the start of the study 
pregnancy and at least one height and weight measurement recorded in the two years 
before the start of the pregnancy. Cases were identified as those with a first diagnosis 
for a developmental disorder on the autism spectrum from birth through 2010 (Read 
Codes: E140.00, E140000, E140.12, E140.13, E140z00, Eu84000, Eu84011, Eu84012, 
Eu84z11, Eu84500, Eu84100, Eu84y00, and Eu84y00). 
Following a review of their entire GPRD record, each case was classified into 
groups representing the following ASD subtypes: autistic disorder, Asperger's disorder, 
pervasive developmental disorder- not otherwise specified (PDD-NOS), and a category 
including individuals with a non-specific ASD diagnosis. If the diagnosis for an individual 
case changed over time the most recent diagnosis was used to determine ASD-subtype. 
Up to four random control subjects without an ASD diagnosis were selected from the 
base population and matched to each case on year of birth, sex, and general practice. 
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3.3.3. Determination of Pregnancy Start Date 
We determined the first day of the last menstrual period (LMP) before the study 
pregnancy and used that as the start date of the study pregnancy. For approximately 
half of the study population (54% of cases and 52% of controls), the LMP was recorded 
in the maternal GPRD record or could be calculated directly from a recorded estimated 
date of delivery. Otherwise, the LMP was calculated as the actual date of delivery minus 
280 days. If there was a code for preterm associated with the study pregnancy or the 
calculated LMP suggested the pregnancy duration was less than 37 weeks, then the 
mother and child electronic medical records were reviewed manually to verify the 
calculated LMP. 
3.3.4. Body Mass Index 
The pre-pregnancy height and weight measurements recorded within the two 
years before and closest to the LMP were used as the measure of maternal pre-
pregnancy BMI, calculated as weight in kilograms divided by the square of height in 
meters (kg/m\ Subjects were classified based on maternal BMI as underweight 
(BM1<18.5), normal weight (BMI 18.5-24.9), overweight (BMI 25-29.9) or obese (BMI 
~30) using the WHO Classification Standard . 
3.3.5. Covariates 
Potential confounders were identified a priori based on a review of the 
literature. In addition to the matched factors (child sex, birth year and general practice), 
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the following variables were abstracted from the GPRD records of all case and control 
mothers and explored as potential confounders of the association between maternal 
BMI and autism occurrence among offspring: maternal age at LMP, pre-pregnancy 
smoking status recorded nearest to the LMP (coded as current, past, never, unknown) 
and pre-pregnancy histories (yes, no) of alcoholism, drug abuse, diabetes (not including 
gestation diabetes in a previous pregnancy) and depression. For each case and control, 
we also identified whether there were any siblings with an ASD diagnosis (yes, no). 
3.3.6. Statistical Analyses 
Descriptive analyses were performed to determine the distribution of covariates 
(frequency and percent for categorical variables and mean and standard deviation for 
continuous variables) for cases and controls, and by BMI category among controls. 
Restricted cubic spline regression was used to assess nonlinearity of the relationship 
between maternal BMI and ASD among offspring (15). Conditional logistic regression 
methods were used to calculate unadjusted odds ratios (OR) controlling for matched 
variables only and multivariable adjusted ORs for the association between maternal 
categorical BMI (reference=normal weight) and the occurrence of ASD overall and of 
specific ASD subtypes, where possible. The initial multivariable model included all 
potential confounders. Each covariate was independently removed from the full 
multivariable model and the variable with the smallest change in OR across levels of BMI 
among those exhibiting a change of <10% was removed. A similar process was employed 
with successive models until a final model was achieved in which all retained variables 
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would result in >10% change in OR for at least one level of BMI if removed. Since none 
of the covariates were retained in the final model using these criteria, results from both 
the unadjusted model (cOR) and fully adjusted models (aOR) are presented. Subjects 
with missing covariate information were excluded from multivariable regression models. 
Unadjusted ORs estimated both including and excluding subjects with missing covariate 
information were not appreciably different, thus the results utilizing the entire study 
population are presented to preserve precision. Stratification by maternal age (~30 
years; >30 years) and genetic susceptibility based on the having a sibling with an ASD 
diagnosis (yes; no) was used to assess effect measure modification. 
3.3.7. Sensitivity Analyses 
We implemented a series of sensitivity analyses to address concerns about 
potential misclassification. We performed an analysis restricted to diagnoses made after 
2001 because preliminary evaluations suggested that nondifferential misclassification of 
specific ASD subtype was possible, particularly prior to 2002 when Asperger's and other 
disorders on the spectrum were likely misclassified as autistic disorder. Nondifferential 
misclassification of the timing of pre-pregnancy BMI could occur since the LMP for many 
mothers was estimated; therefore, we completed analyses restricted to mothers with a 
GP-recorded LMP. There was inter-individual variability in the proximity of the most 
recent GP-recorded BMI information to the LMP, so we completed separate analyses for 
individuals with BMI measurements within 12 months of the start of the study 
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pregnancy and for those with measurements more than 12 months before the start of 
the study pregnancy. 
3.4. RESULTS 
3.4.1. Population Characteristics 
Approximately, 84% of children with a diagnosis on the autism spectrum who 
were registered with the GPRD at birth during the study period 1993-2008 were able to 
be matched to their mother in the GPRD. We identified a total 889 individuals with a 
diagnosis on the autism spectrum, of which 615 (69.2%) were diagnosed with autism, 
244 (27.4%) were diagnosed with Asperger's disorder, and 30 (3.4%) were diagnosed 
with PDD-NOS or more generally as having an autism spectrum disorder. On average, 
cases were first diagnosed by 6.2 years of age (standard deviation ±3.2 years) with 
autism generally diagnosed at earlier ages than Asperger's disorder (5.4 ±2.9 years and 
8.2 ±3.0 years respectively). ASD cases were predominantly male (n=724, 81.4%) 
independent of subtype. There were 3530 control subjects identified from the same 
source population as the ASD case subjects. All but 16 cases (98.1%) were matched to 
four controls. 
Distributions of selected child and maternal characteristics among ASD case and 
non-ASD control subjects are presented in Table 3.1. Case mothers tended to be slightly 
older than control mothers (50.6% of case mothers versus 47.3% of control mothers 
were 30 years or older at the start of the study pregnancy). Case mothers were 
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somewhat more likely to be ever smokers (40.2% versus 37.5%) and to have a history of 
diabetes (1.1% versus 0.6%) or depression (17.8% versus 13.9%). A higher proportion of 
cases (8.4%) than controls (1.3%) had a sibling with an autism spectrum disorder. 
Maternal histories for drug and alcohol abuse did not differ for cases and controls. In 
general, these trends were similar for both autism and Asperger's cases compared to 
controls. 
Distributions of selected child and maternal characteristics by BMI category 
among controls are presented in Table 3.2. The majority of control mothers were 
normal weight (57.8%), but 4% were underweight, 23.7% were overweight and 14.6% 
were obese. The maternal age distribution differed by BMI category. Specifically, 
compared to normal weight mothers, underweight mothers were younger (4.8% versus 
18.6% younger than 20 years) whereas overweight and obese were older (18.4% and 
17.3% over 35 years, respectively, versus 14.6% among normal weight). The extreme 
maternal BMI categories, underweight and obese, had higher proportions of ever 
smokers (43.6% and 41.6% versus 35.9%), pre-pregnancy depression (22.9% and 20.0% 
versus 11.1%) and alcoholism (2.1% and 3.5% versus 1.8%) versus normal weight. Pre-
pregnancy diabetes was more prevalent with higher BMI and drug abuse was more 
common with lower BMI. 
3.4.2. Maternal Body Mass Index and Autism Spectrum Disorders 
Conditional restricted cubic spline regression revealed that the association 
between maternal BMI and ASD occurrence among offspring was nonlinear and J-
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shaped (p-value for test for curvature=0.013; overall significance of curve=0.003), with 
extremes in maternal BMI being associated with the largest increases in ASD risk (Figure 
3.1). The ORs conditional on matching factors for the effect of maternal underweight, 
overweight and obesity on ASD among offspring were 1.43 (95% Cl 1.01, 2.04), ' 1.21 
(95% Cl 1.01, 1.45) and 1.54 (95% Cl 1.26, 1.89}, compared to normal weight mothers 
(Table 3.3). None of the variables assessed were meaningful confounders of the 
observed associations as evidenced by effect estimates that were essentially unchanged 
following full multivariable adjustment for maternal age, pre-pregnancy depression, 
diabetes, smoking status, drug abuse, and alcoholism. Results for autistic disorder were 
nearly identical to those observed for any ASD overall, while ORs for Asperger's were 
similar but marginally attenuated. There were too few cases of POD-NOS to conduct a 
stratified analysis. 
Unadjusted and multivariable adjusted results from conditional regression 
analyses stratified by maternal age at the start of the study pregnancy are presented in 
Table 3.4. ORs for the effects of maternal underweight, overweight and obesity on ASD 
risk among offspring differed by maternal age. Underweight was associated with 
elevated ASD risk among mothers 30 years of age or older [cOR: 2.13 (95% Cl 1.03, 
4.43)], but not among mothers younger than 30 years [cOR for maternal age 25-29 
years: 1.09, (95% Cl 0.42, 2.85), cOR for maternal age <25 years: 1.16 (95% Cl 0.49, 
2.77)]. Maternal overweight was associated with an increase in ASD risk in offspring only 
for mothers 25-29 years of age [cOR: 1.89, (95% Cl 1.19, 2.98)]. Stratum-specific ORs for 
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the effect of maternal obesity suggested increases in ASD risk ranging from 1.32-2.20 
dependent upon age, where obesity was associated with more pronounced increases 
among younger mothers. 
3.4.3. Sensitivity Analyses 
Results from conditional logistic regression analyses restricted to study subjects 
with no siblings with an ASD diagnosis are presented in Table 3.5. Findings among this 
restricted population were similar to those observed for the overall study population. 
There were insufficient data to evaluate associations separately for cases and controls 
who had a sibling with an ASD diagnosis. 
When analyses were restricted to ASD diagnoses made after 2001 (Table 3.6), 
the association between maternal underweight and autistic disorder was strengthened 
[cOR: 1.57 (95% Cl 0.96, 2.57)], whereas the relationship with Asperger's disorder was 
attenuated (cOR: 1.18, 95% Cl 0.60, 2.34) compared to results for the entire study 
population . Results for maternal overweight and obesity were unchanged. 
Findings from analyses restricted to pregnancies with a GP-recorded LMP did not 
differ from those observed for the entire study population (Table 3.7). Analyses 
stratified by timing of BMI measurement relative to the start of the study pregnancy 
showed that associations were generally stronger for BMI measurements obtained 
closer to the start of the study pregnancy (Table 3.8). 
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3.5. DISCUSSION 
In this study, we observed a modest non-linear association between maternal 
pre-pregnancy body mass index and autism spectrum disorders among offspring, with 
extremes being associated with higher risk compared to normal weight for the overall 
study population. The odds ratios for maternal underweight and obesity were 1.4 (95% 
Cl: 1.0, 2.0) and 1.5 (95% Cl: 1.3, 1.9), respectively. However, the relationship between 
maternal BMI and ASD risk differed by maternal age. Maternal underweight was 
significantly associated with an increase in ASD only among mothers over 30 years of 
age. Maternal obesity was associated with increased risk for ASD irrespective of age, but 
the relative association was most prominent among mothers under 30 years of age. 
To our knowledge, we are the first to identify an elevated risk associated with 
maternal underweight. A low maternal pre-pregnancy BMI may be a marker for 
undernutrition and limited availability of micronutrients, including prenatal deficiencies 
of folic acid, iodine, and iron, which have been implicated in neurologic deficits and 
developmental disorders (16). Why underweight would only be associated with an 
elevated risk for ASD among offspring of older mothers is unclear. One possibility is that 
our chosen BMI categorization method preferentially misclassified young normal weight 
women as underweight (i.e., younger than 20 years) thus producing a downward bias of 
the resulting OR. The BMI cut-points we utilized are widely accepted as standard and 
are based on relationships with morbidity and mortality in adults, but they may not be 
appropriate for adolescents for whom age-specific cut-points have been proposed due 
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to their continued growth and development (17, 18). However, results of sub-analyses 
in which adolescent mothers were re-classified to BMI categories based on an age-
specific reference (17) were not materially different. Another possibility is that 
underweight in older women maybe more likely to represent underlying illness than 
underweight in younger women. 
Our findings relating maternal pre-pregnancy obesity to ASD among offspring are 
similar to those of others. Dodds et al. (6) reported that maternal pre-pregnancy weight 
~90 kg was associated with a 58% higher risk for ASD among offspring compared to 
maternal weight <90 kg among a cohort of children born from 1990 to 2002 in Nova 
Scotia. More recently, maternal obesity (BMI >30 kg/m 3) was found to be associated 
with a 67% higher risk for ASD in the CHARGE study, a population-based case-control 
study in California (7). Our observed age-related differences in the association between 
maternal obesity and ASD occurrence may be due in part to differences in the baseline 
risk in the two subpopulations. Even among normal weight women, advanced age has 
been associated with an increased risk for ASD among offspring (19-25). Therefore, the 
relative effect of obesity on ASD occurrence among offspring may be diluted for older 
women than younger women. 
An association between maternal obesity and ASD among offspring is plausible 
based on mounting evidence from animal experiments and human studies that suggest 
activation of the maternal immune system may be a risk factor for autism (26). Although 
maternal circulating cytokine levels vary over the course of pregnancy, concentrations 
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are dependent upon BMI and age (27). Pro-inflammatory cytokine levels (i.e., IL-6) are 
higher in obese women compared to those with normal BMI (28, 29). Therefore, 
pregnancies among overweight or obese women may be exposed to higher levels of 
maternal inflammatory cytokines which pass to the fetal circulation and cross the fetal 
blood-brain barrier and may lead to abnormal neuronal growth and differentiation 
within the fetal brain (26) . 
Our study has several strengths. It consisted of a large sample of cases and 
matched controls in which all information was recorded prospectively by trained 
medical personnel, thereby eliminating the possibility of bias due to differential parental 
recall. Nesting our study within an established UK primary care database also minimized 
the potential for self-selection bias that would be a greater concern in studies that rely 
on information from mothers who volunteered to participate. Whereas previous studies 
focused only on maternal obesity, we utilized spline regression to assess nonlinearity of 
the relationship between the complete range of maternal BMI and ASD among 
offspring. We also had the ability to evaluate associations for specific ASD subtypes. 
Despite the strengths of the study, our results should be considered in light of 
some potential limitations. We relied exclusively on Read codes for the identification of 
cases, thus they were not validated by standardized clinical assessment which may have 
led to some misclassification and the observed associations were attenuated. However, 
a recent review of GPRD computerized records of ASD against all available clinical 
reports including GP notes, consultant, speech therapy and educational psychologist 
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reports, verified over 90% of diagnoses (12), suggesting over-ascertainment was low. In 
early years of the study ASD subtype specific diagnosis codes did not exist or were 
underutilized. In a sub-analysis restricted to diagnoses made after 2001, we found no 
association between underweight and Asperger's and a stronger association between 
underweight and autistic disorder suggesting some subtype misclassification in the 
earlier years. 
Exposure misclassification is also a possibility. We used the height and weight 
information recorded closest to the start of the study pregnancy and there was some 
variation in this proximity across subjects. Analyses stratified by timing of BMI 
measurements relative to the start of the study pregnancy revealed stronger 
associations for BMI measured closer to the actual start of pregnancy. Thus, suggesting 
that the observed associations may be real because measurements made closer to the 
start of the study pregnancy are the more valid measure of pre-pregnancy BMI status. 
We estimated the start date of the index pregnancy for over half of the study population 
so for some of those mothers we may have utilized measurements that reflected their 
BMI during the study pregnancy. However, results of analyses restricted to mothers 
with a GP-recorded LMP did not differ from the full analysis suggesting that any 
misclassification of pre-pregnancy BMI due to our method of estimating the start date 
of the study pregnancy was negligible. 
The source population for our study was limited to those children who could be 
matched to a mother in the GPRD, which could introduce selection bias if a successful 
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match was related to maternal BMI and differed for cases and controls. However, the 
proportion of ASD cases in the GPRD that could be successfully matched to their mother 
was high and did not differ from the match rate for all births into the GPRD over the 
study period. 
Our study was also restricted to ASD cases and matched controls whose mothers 
had a documented BMI measurement within 2 years before the start of the study 
pregnancy. It is possible that the availability of such a BMI is related to actual BMI 
differentially for cases and controls. We evaluated the distribution of BMI 
measurements among ASD cases and controls whose mothers had measurements 
within 10 years before the study pregnancy. By relaxing the definition of the pre-
pregnancy window, the proportions of maternal normal weight, overweight, and obesity 
changed similarly for both cases and controls compared to the distributions observed in 
the current study. However, the proportion of underweight mothers increased about 
80% for controls and only 30% for cases. This trend suggests that the observed 
association between maternal underweight and ASD in offspring may be partially 
explained by differential missingness (selection bias). 
In conclusion, the GPRD, a population-based data resource with the ability to link 
maternal records with those of their offspring, enabled us to evaluate the risk for ASD in 
relation to maternal BMI using a nested case-control design. Our results suggest that 
extremes in maternal BMI may be associated with modest increases in the risk for ASD 
among offspring. 
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Table 3.1. Distributions of selected child and maternal characteristics among ASD case and non-ASD control subjects, 
GPRD singleton live births 1993-2008 
Any ASD (N=889) Autism (n=615) Asperger's (n=244) Other (n=30) Controls (N=3530) 
n % n % n % n % n % 
Child Sex 
Male 724 81.4 493 80.2 209 85.7 22 9.0 2870 81.3 
Female 165 18.6 122 19.8 35 14.3 8 3.3 660 18.7 
Child Year of Birth 
1993-1996 232 26.2 129 21.0 93 38.1 5 23.8 937 26.5 
1997-2000 310 34.9 206 33.5 94 38.5 7 33.3 1215 34.4 
2001-2004 260 29.2 199 32.4 54 22.1 6 28.6 1022 29.0 
2005-2008 87 9.8 81 13.2 3 1.2 3 14.3 356 10.1 
Maternal Age, Mean (sd) 29.4 (5.6) 29.7 (5.6) 29.0 (5.4) 27.9 (5.7) 29.0 (5.4) 
<20 years 34 3.8 21 3.4 10 4.1 3 10.0 155 4.4 
0"\ 20-24 years 148 16.6 97 15.8 46 18.9 5 16.7 584 16.5 
-...! 
25-29 years 257 28.9 180 29.3 68 27.9 9 30.0 1121 31 .8 
30-34 years 289 32.5 196 31 .9 84 34.4 9 30.0 1116 31.6 
35+ 161 18.1 121 19.7 36 14.8 4 13.3 554 15.7 
Maternal Smoking 
Current 100 11 .2 74 12.0 25 10.2 1 3.3 373 10.6 
Former 257 28.9 171 27.8 75 30.7 11 36.7 950 26.9 
Never 502 56.5 350 56.9 136 55.7 16 53.3 2082 59.0 
Missing 30 3.4 20 3.3 8 3.3 2 6.7 125 3.5 
Maternal Diabetes 
Yes 10 1.1 9 1.5 1 0.4 0 0.0 21 0.6 
No 879 98.9 606 98.5 243 99.6 30 100.0 3509 99.4 
Maternal Depression 
Yes 158 17.8 110 17.9 42 17.2 6 20.0 489 13.9 
No 731 82.2 505 82.1 202 82.8 24 80.0 3041 86.1 
Table 3.1. (continued) Distributions of selected child and maternal characteristics among ASD case and non-ASD control 
subjects, GPRD singleton live births 1993-2008 
Any ASD (N=889) Autism (n=615) Asperger's (n=244) Other (n=30) Controls (N=3530) 
n % n % n % n % n % 
Maternal Drug Abuse 
Yes 5 0.6 5 0.8 0 0.0 0 0.0 17 0.5 
No 884 99.4 610 99.2 244 100.0 30 100.0 3513 99.5 
Maternal Alcoholism 
Yes 18 2.0 13 2.1 5 2.0 0 0.0 73 2.1 
No 871 98.0 602 97.9 239 98.0 30 100.0 3457 97.9 
Sibling with ASD Diagnosis 
Yes 75 8.4 59 9.6 15 6.1 1 3.3 45 1.3 
No 813 91.5 555 90.2 229 93.9 29 96.7 3484 98.7 
(j) 
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Table 3.2. Distributions of selected child and maternal characteristics by body mass index 
category among control subjects, GPRD singleton live birth 1993-2008 
Underweight Normal Weight Overweight Obese 
n % n % n % n % 
Total 140 4.0 2040 57.8 836 23.7 514 14.6 
Maternal Age, Mean (sd) 26.2 (6 .1) 28.8 (5.4) 29.6 (5.2) 29.5 (5 .1) 
<20 years 26 18.6 97 4.8 22 2.6 10 1.9 
20-24 years 29 20.7 349 17.1 133 15.9 73 14.2 
25-29 years 44 31.4 640 31.4 248 29.7 189 36.8 
30-34 years 27 19.3 657 32.2 279 33.4 153 29.8 
35+ 14 10.0 297 14.6 154 18.4 89 17.3 
Maternal Smoking 
Current 9 6.4 198 9.7 101 12.1 65 12.6 
Former 52 37.1 535 26.2 214 25.6 149 29.0 
None 71 50.7 1237 60.6 496 59.3 278 54.1 
Missing 8 5.7 70 3.4 25 3.0 22 4.3 
Maternal Diabetes 
Yes 0 0.0 5 0.2 9 1.1 7 1.4 
No 140 100.0 2035 99.8 827 98.9 507 98.6 
Maternal Depression 
Yes 32 22.9 226 11.1 128 15.3 103 20.0 
No 108 77.1 1814 88.9 708 84.7 411 80.0 
Maternal Drug Abuse 
Yes 2 1.4 10 0.5 4 0.5 1 0.2 
No 138 98.6 2030 99.5 832 99.5 513 99.8 
Maternal Alcoholism 
Yes 3 2.1 36 1.8 16 1.9 18 3.5 
No 137 97.9 2004 98.2 820 98.1 496 96.5 
Sibling with ASD Diagnosis 
Yes 0 0.0 24 1.2 8 1.0 13 2.5 
No 140 100 2015 98.8 828 99.0 501 97.5 
69 
-..J 
0 
Table 3.3. Conditional unadjusted and multivariable adjusted odds ratios for the association 
between maternal BMI and ASD among offspring, GPRD singleton live birth 1993-2008 
Cases (n) Controls (n) ORadjusted ORunadjusted 
Any Autism Spectrum Disorder 
Underweight, BMI<18.5 44 140 1.45 (1.01' 2.08) 1.43 (1.01' 2.04) 
Normal weight, BMI18.5-24.9 450 2040 reference reference 
Overweight, BMI25-29.9 222 836 1.18 (0.99, 1.42) 1.21 (1.01' 1.45) 
Obese, BMI ~30 173 514 1.50 (1.22, 1.84) 1.54 (1.26, 1.89) 
Autistic Disorder 
Underweight, BMI<18.5 28 140 1.44 (0.92, 2.27) 1.38 (0.88, 2.16) 
Normal weight, BMI18.5-24.9 308 2040 reference reference 
Overweight, BMI25-29.9 156 836 1.17 (0.94, 1.46) 1.23 (0 .99, 1.52) 
Obese, BMI ~30 123 514 1.51 (1.18, 1.93) 1.56 (1.22, 1.99) 
Asperger's Disorder 
Underweight, BMI<18.5 13 140 1.30 (0.69, 2.48) 1.32 (0.70, 2.50) 
Normal weight, BMI18.5-24.9 129 2040 reference reference 
Overweight, BMI25-29.9 57 836 1.18 (0.83, 1.69) 1.18 (0.83, 1.68) 
Obese, BMI ~30 45 514 1.45 (0.97, 2.15) 1.47 (0.99, 2.17) 
Adjusted model odds ratios adjusted for maternal age (continuous), maternal pre-pregnancy depression, 
diabetes, smoking status, drug abuse, alcoholism, in addition to matching factors (birth year, sex, and 
Unadjusted model odds ratios adjusted for matching factors (birth year, sex, and general practice) only 
The number of cases with autistic disorder and Asperger's disorder do not sum up to the number with any 
because there are individuals with PDD-NOS or a more general "autism spectrum disorder" that are not 
included here. There were too few PDD-NOS cases to perform analyses for that subtype 
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Table 3.4. Conditional unadjusted and multivariable adjusted odds ratios for the 
association between maternal BMI and Autism spectrum disorders among offspring 
stratified by maternal age at the start of the study pregnancy, GPRD singleton live birth 
1993-2008 
Cases (n) Controls (n) ORadjusted ORunadjusted 
Maternal age <25 years 
Underweight, BMI<18.5 15 55 1.05 (0.43, 2.58) 1.16 (0.49, 2.77) 
Normal weight, BMI18.5-24.9 90 446 reference reference 
Overweight, BMI25-29.9 41 155 1.07 (0.60, 1.92) 1.11 (0.63, 1.95) 
Obese, BMI ~30 36 83 2.16 (1.09, 4.30) 2.20 (1.12, 4.31) 
Maternal age 25-29 years 
Underweight, BMI<18.5 12 44 0.93 (0.34, 2.51) 1.09 (0.42, 2.85) 
Normal weight, BMI18.5-24.9 117 640 reference reference 
Overweight, BMI25-29.9 73 248 1.89 (1 .19, 2.98) 1.82 (1.17, 2.84) 
Obese, BMI ~30 55 189 1.82 (1.08, 3.09) 1.95 (1.18, 3.23) 
Maternal age ~30 years 
Underweight, BMI<18.5 17 41 1.94 (0.97, 3.89) 2.13 (1.03, 4.43) 
Normal weight, BMI18.5-24.9 243 954 reference reference 
Overweight, BMI25-29.9 108 433 1.00 (0.75, 1.33) 0.95 (0.71' 1.28) 
Obese, BMI ~30 82 242 1.29 (0.92, 1.81) 1.32 ~0.96, 1.86) 
Adjusted model odds ratios adjusted for maternal age (continuous), maternal pre-pregnancy depression, 
diabetes, smoking status, drug abuse, alcoholism, in addition to matching factors (birth year, sex, and 
general practice); Unadjusted model odds ratios adjusted for matching factors (birth year, sex, and 
general practice) only 
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Table 3.5. Conditional unadjusted and multivariable adjusted odds ratios for the association 
between maternal BMI and ASD among offspring -restricted to cases and controls with no 
siblings with an autism spectrum disorder diagnosis, GPRD singleton live birth 1993-2008 
Cases (n) Controls (n) ORadjusted ORunadjusted 
Any Autism Spectrum Disorder 
Underweight, BMI<18.5 42 140 1.57 (1.08, 2.28) 1.54 (1.07, 2.23) 
Normal weight, BMI18.5-24.9 406 2015 reference reference 
Overweight, BMI25-29.9 212 828 1.20 (1.00, 1.45) 1.24 (1.03, 1.50) 
Obese, BMI ~30 153 501 1.49 (1.19, 1.85) 1.53 (1.24, 1.90) 
Autistic Disorder 
Underweight, BMI<18.5 27 94 1.62 (1.01' 2.60) 1.55 (0.97, 2.47) 
Normal weight, BMI18.5-24.9 273 1388 reference reference 
Overweight, BMI25-29.9 147 578 1.18 (0.94, 1.48) 1.25 (1.00, 1.56) 
Obese, BMI ~30 108 352 1.54(1.18,2.00) 1.61 (1.24,2.08) 
Asperger's Disorder 
Underweight, BMI<18.5 12 43 1.29 (0.66, 2.51) 1.32 (0.68, 2.58) 
Normal weight, BMI18.5-24.9 120 561 reference reference 
Overweight, BMI25-29.9 56 214 1.26 (0.87, 1.81) 1.25 (0.87, 1.79) 
Obese, BMI ~30 41 136 1.37 (0.91' 2.07) 1.37 (0.91' 2.06) 
Adjusted model odds ratios adjusted for maternal age (continuous), maternal pre-pregnancy depression, 
diabetes, smoking status, drug abuse, alcoholism, in addition to matching factors (birth year, sex, and 
general practice); Unadjusted model odds ratios adjusted for matching factors (birth year, sex, and general 
practice) only; the number of cases with autistic disorder and Asperger's disorder do not sum up to the 
number with any because there are individuals with POD-NOS or a more general "autism spectrum 
disorder" that are not included here. There were too few PDD-NOS cases to perform analyses for that 
subtype 
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Table 3.6. Conditional unadjusted and multivariable adjusted odds ratios for the 
association between maternal BMI and ASD among offspring restricted to diagnoses after 
2001, GPRD singleton live birth 1993-2008 
Cases (n) Controls (n) ORadjusted ORunadjusted 
Any Autism Spectrum Disorder 
Underweight, BMI<18.5 36 114 1.45 (0.98, 2.15) 1.46 (0.99, 2.16) 
Normal weight, BMI18.5-24.9 371 1713 reference reference 
Overweight, BMI25-29.9 191 697 1.24 (1.02, 1.51) 1.27 (1 .05, 1.55) 
Obese, BMI ~30 154 460 1.51 (1.21, 1.87) 1.56 (1.25, 1.93) 
Autistic Disorder 
Underweight, BMI<18.5 23 114 1.61 (0.98, 2.65) 1.57 (0.96, 2.57) 
Normal weight, BMI18.5-24.9 239 1713 reference reference 
Overweight, BMI25-29.9 132 697 1.29 (1.01' 1.64) 1.34 (1.05, 1.69) 
Obese, BMI ~30 109 460 1.56 (1.20, 2.03) 1.63 (1.26, 2.11) 
Asperger's Disorder 
Underweight, BMI<18.5 11 114 1.13 (0.57, 2.27) 1.18 (0.60, 2.34) 
Normal weight, BMI18.5-24.9 121 1713 reference reference 
Overweight, BMI25-29.9 53 697 1.16 (0.81 , 1.69) 1.17 (0.81, 1.68) 
Obese, BMI ~30 41 460 1.36 (0.90, 2.06) 1.38 (0.92, 2.08) 
Adjusted model odds ratios adjusted for maternal age (continuous), maternal pre-pregnancy depression, 
diabetes, smoking status, drug abuse, alcoholism, in addition to matching factors (birth year, sex, and 
general practice); Unadjusted model odds ratios adjusted for matching factors (birth year, sex, and 
general practice) only; The number of cases with autistic disorder and Asperger's disorder do not sum up 
to the number with Any ASD because there are individuals with POD-NOS or a more general "autism 
spectrum disorder" that are not included here. There were too few POD-NOS cases to perform analyses 
for that subtype 
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Table 3.7. Conditional unadjusted and multivariable adjusted odds ratios for the 
association between maternal BMI and ASD among offspring restricted to individuals 
with a GP-recorded start date of the study pregnancy, GPRD singleton live birth 1993-
2008 
Cases (n) Controls (n) ORadjusted ORunadjusted 
Any Autism Spectrum Disorder 
Underweight, BMI<18.5 28 71 1.34 (0.82, 2.18) 1.35 (0.76, 2.40) 
Normal weight, BMI18.5-24.9 239 1059 reference reference 
Overweight, BMI25-29.9 115 431 1.23 (0.95, 1.61) 1.26 (0.93, 1.71) 
Obese, BMI ~30 99 271 1.49(1.11,2.00) 1.55(1.11,2.17) 
Autistic Disorder 
Underweight, BMI<18.5 18 71 1.36 (0.76, 2.45) 1.41 (0.87, 2.27) 
Normal weight, BMI18.5-24.9 173 1059 reference reference 
Overweight, BMI25-29.9 85 431 1.24 (0.91' 1.69) 1.24 (0.96, 1.61) 
Obese, BMI ~30 72 271 1.54 (1.10, 2.18) 1.50 (1.13, 2.01) 
Asperger's Disorder 
Underweight, BMI<18.5 7 71 1.25 (0.47, 3.36) 1.26 (0.49, 3.29) 
Normal weight, BMI18.5-24.9 61 1059 reference reference 
Overweight, BMI25-29.9 26 431 1.18 (0.69, 2.02) 1.19 (0.71, 2.00) 
Obese, BMI ~30 27 271 1.55 (0.85, 2.85) 1.56 (0.87, 2.81) 
Adjusted model odds ratios adjusted for maternal age (continuous), maternal pre-pregnancy depression, 
diabetes , smoking status, drug abuse, alcoholism , in addition to matching factors (birth year, sex, and 
general practice); Unadjusted model odds ratios adjusted for matching factors (birth year, sex, and 
general practice) only; The number of cases with autistic disorder and Asperger's disorder do not sum 
up to the number with Any ASD because there are individuals with POD-NOS or a more general "autism 
spectrum disorder" that are not included here. There were too few POD-NOS cases to perform 
analyses for that subtype 
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Table 3.8. Conditional unadjusted and multivariable adjusted odds ratios for the 
association between maternal BMI category and ASD among offspring by timing of BMI 
measurement relative to the start of the study pregnancy, GPRD singleton live births 
1993-2008 
Cases (n) Controls (n) ORadjusted ORunadjusted 
BMI measured within 12 months before LMP 
Underweight, BMI<18.5 26 
Normal weight, BMI18.5-24.9 221 
Overweight, BMI25-29.9 129 
Obese, BMI ~30 110 
BMI measured more than 12 months before LMP 
Underweight, BMI<18.5 18 
Normal weight, BMI18.5-24.9 229 
Overweight, BMI25-29.9 93 
Obese, BMI ~30 63 
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reference reference 
1.09 (0.79, 1.50) 1.05 (0.77, 1.44) 
1.33 (0.89, 1.97) 1.36 (0.92, 1.99) 
Adjusted model odds ratios adjusted for maternal age (continuous), maternal pre-pregnancy depression, 
diabetes, smoking status , drug abuse, alcoholism, in addition to matching factors (birth year, sex, and 
general practice); Unadjusted model odds ratios adjusted for matching factors (birth year, sex, and 
general practice) only 
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Figure 3.1. Multivariable adjusted restricted cubic spline regression analysis assessing nonlinearity of the association 
between maternal body mass index and occurrence of autism spectrum disorders among offspring, GPRD singleton live 
births 1993-2008 
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4. SHORT INTERPREGNANCY INTERVAL, MATERNAL HISTORY OF PREGNANCY LOSS 
AND AUTISM SPECTRUM DISORDER AMONG OFFSPRING 
4.1. ABSTRACT 
We explored maternal reproductive history with respect to autism in offspring. Three 
previous studies have attributed short inter-pregnancy intervals between first and 
second live births to a higher risk for autism spectrum disorders (ASD). The relationship 
between maternal history of pregnancy loss, particularly recurrent loss, and ASD has not 
been well-studied. We assessed the associations of short interpregnancy interval (IPI) 
and maternal history of pregnancy loss with the occurrence of ASD diagnosed by age 3 
years among individuals born in Massachusetts from 2000-2008 to multigravida. ASD 
cases were identified through the MA Early Intervention program and linked to vital 
statistic information via the Pregnancy to Early Life Longitudinal data system. Non-
linearity of the association between maternal IPI and ASD was assessed with restricted 
cubic splines. Generalized linear models were used to calculate crude and multivariable 
adjusted odds ratios for the associations of interest. The association between maternal 
IPI and ASD occurrence was non-linear and J-shaped (p<O.OOl), where IPI lengths less 
than 18 months and longer than 60 months were associated with an increased risk for 
ASD. The association with short IPI was stronger for mothers less than 25 years and was 
restricted to consecutive live births. A history of pregnancy loss among primapara was 
associated with a modest increase in ASD risk. Our findings are consistent with previous 
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reports and provide some support for the maternal nutritional depletion hypothesis as a 
potential mechanism for the association between IPI and ASD. 
4.2.1NTRODUCTION 
Assessing the associations with factors related to maternal reproductive history may 
provide insight into potential prenatal causal mechanisms underlying the autism 
spectrum disorders. 
lnterpregnancy interval refers to the time period from the completion of one 
pregnancy to the conception of the next consecutive pregnancy. Extremes in the length 
of interpregnancy interval, both long and short, have been linked to adverse pregnancy 
outcomes including preterm birth, low birth weight, small-for-gestational age, infant 
mortality, and some birth defects (1-5). 
A case-control study found that women who had interpregnancy intervals (IPI) 
less than 18 months were at increased risk of having a child with ASD (6). Similar results 
were observed in a population-based cohort study from California; specifically, IPis less 
than 24 months were associated with increased occurrence of ASD in second-born 
children with the largest elevation in risk occurring for intervals of less than 12 months 
(7) . Most recently, a nationwide Norwegian study found a U-shaped relationship with 
interpregnancy interval. ASD subtype-specific analyses suggested that the effect may be 
restricted to autistic disorder only (8). 
Mechanisms have been proposed for both long and short intervals. Long 
interpregnancy intervals may reflect infertility and its treatment which have been 
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associated with an increased risk for autism, albeit inconsistently (9-11) . Buchmayer et 
al. (12) suggested that longer intervals related to repeated early pregnancy losses and 
difficulties in conceiving, and may also be indirect measures of prenatal infections, 
which have been hypothesized to increase the risk of autistic disorders in the offspring. 
Maternal nutritional depletion is a leading theory for the association of short IPI with 
adverse pregnancy outcomes (13). Other possible mechanisms may involve a maternal 
stress response or persistent systemic inflammatory response in the postnatal period. 
Previous studies have evaluated the impact of interval length only between consecutive 
live births and have not assessed the potential for effect modification by the outcome of 
the preceding pregnancy or maternal age. Exploring these factors allows for better 
understanding of the potential biological mechanism underlying the association 
between interpregnancy interval and autism risk. 
Given the mounting evidence of involvement of maternal immune system 
activation in the etiology of ASD (14-17) it is possible that a previous pregnancy loss may 
be associated with an increase in ASD risk. 
Cytokine levels (i.e., IL-6 and IL-8) in plasma and the cervical mucus of patients 
following a miscarriage are higher than those of women following a live birth (18, 19). 
There are no studies assessing how long after an isolated miscarriage pro-inflammatory 
cytokines remain elevated. In contrast, women with a history of recurrent miscarriage (3 
or more consecutive miscarriages) have been shown to exhibit abnormally high cytokine 
expression even when not pregnant (20, 21) . 
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Because of the likely differences in pathophysiology, this study involves separate 
hypotheses for isolated loss and recurrent loss in relation to ASD occurrence. We 
hypothesize that only following a short interpregnancy interval would an isolated loss be 
associated with a higher risk of ASD in the next pregnancy. With regard to recurrent 
loss, we hypothesize that there will be a higher risk of ASD among children whose 
mothers have a history of recurrent miscarriage compared to those who do not, 
regardless of interpregnancy interval length. 
We evaluate whether a short interpregnancy interval is associated with higher 
risk of ASD and whether the outcome of the preceding pregnancy or maternal age 
modifies this association. Separately, we evaluated whether maternal history of 
recurrent miscarriage is associated with a higher risk of ASD. 
4.3. METHODS 
4.3.1. Data Source 
This study utilized Massachusetts birth and death records and Early Intervention (EI) 
program data from 2000 through 2011 linked through the Pregnancy to Early Life 
Longitudinal data system (PELL) for individuals born between 2000 and 2008. 
El is a program designed to help infants and toddlers who have developmental 
delays including those with ASD, or those who are at risk for such delays. All cities and 
towns in Massachusetts have El programs that serve their residents. Anyone who has 
concerns about a child can make a referral for El services including parents, other 
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relatives, child-care providers, teachers, and doctors. A multidisciplinary team of 
specialists evaluates each referred child using the Michigan Early Intervention 
Developmental Profile and the Battelle Developmental lnventory-2 to determine 
eligibility. The specialists then develop Individualized Family Service Plans (IFSP) make 
recommendations to El providers. A specific IFSP may include physical or occupational 
therapy, speech or language therapy, psychological services, social services, educational 
services, nursing care, behavior modification, nutritional counseling, family counseling 
and home visits, assistive technology, other specialty services. Eligibility for El services 
ends when a child turns three years of age or if a child no longer meets the 
developmental delay requirements. 
There is never a fee for an El evaluation, IFSP development, or coordination of 
services. Individual El services are free for many families including those with incomes 
below 300% of the Federal Poverty Guidelines, children in foster care and children with 
any type of MassHealth insurance. Families that do not qualify for free El services are 
charged an annual fee based on income, but most health insurance plans cover this fee. 
The Massachusetts Department of Public Health has the responsibility for administering 
and overseeing the statewide system of Early Intervention services, for certifying 
programs and coordinating funding sources, and for carrying out monitoring and 
technical assistance activities. 
PELL represents a public-private partnership between the Boston University 
School of Public Health, the Massachusetts Department of Public Health, and the 
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Centers for Disease Control and Prevention. It is a relational data system composed of 
individual datasets that are linked together by randomly generated unique identifiers 
for mother and infant. A 9-step algorithm is used to match early-intervention program 
data with resident birth and fetal death certificate records on various combinations of a 
child's first and last names, mother's last name, child's date of birth, mother's date of 
birth, child's gender, zip code, and Soundex, a SAS function used to combine alpha-
numeric data on the basis of similar but not exact sounds. The overall linkage rate of 
early-intervention records to a birth certificate was 87.3%. 
4.3.2. Study Population 
The study population included all singleton live births from 2000 through 2008 to MA 
residents who had at least one previous pregnancy as indicated by a gravidity greater >1 
in the birth record. Children with an ASD were identified as those with a documented 
diagnosis of autistic disorder (lCD code 299.00), Asperger's disorder (299.80), pervasive 
developmental disorder - not otherwise specified (299.90}, or "autism spectrum 
disorder" in the El database or an El Specialty Services Program claim indicating they 
had received ASD-related services. El data records for 2000- 2011, inclusive, were used 
to identify ASD cases, so all subjects were followed for ASD diagnosis to age 3 years. 
4.3.3. lnterpregnancy Interval and Pregnancy Loss 
lnterpregnancy interval was computed as the time period in completed months 
between the dates of the most recent previous live birth or loss and the estimated date 
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of conception of the study child. The date of conception was calculated as the date of 
birth minus the clinical estimate of the gestational age at birth. When the day was 
missing for the end of the previous pregnancy, the 15th of the month was used to 
compute interpregnancy interval. Subjects were assigned to an interval category based 
on their computed interpregnancy interval (<6, 6-11, 12-17, 18-23, 24-29, 30-35, 36-41, 
42-48, 48-53, 54-59 and 60+ months). 
Subjects were further classified with respect to maternal history of pregnancy 
loss (no history of loss; history of loss but at least one previous live birth; history of loss 
with no previous live birth). Those with a history of loss were further classified with 
respect to number of consecutive losses (1, 2, 3 or more). 
4.3.4. Covariates 
Covariate information was obtained from the birth certificates of each subject. 
Covariates were initially selected a priori based on previous literature. A final set of 
potential confounders was selected based on associations with the exposures of interest 
(interpregnancy interval and pregnancy loss) and ASD occurrence. 
Variables considered as potential confounders include maternal and paternal 
age, marital status (married to father, married-not to father, unmarried), maternal 
education (less than high school, high school graduate, some college, 4 or more years of 
college), maternal race, gravidity (for interpregnancy interval analysis), fertility 
treatment, maternal pre-pregnancy histories (yes, no) of diabetes, hypertension, seizure 
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disorders and anemia, and maternal smoking and alcohol consumption during 
pregnancy (yes, no). 
4.3.5. Statistical Analyses 
The prevalence of ASD was assessed by level of each covariate. Distributions of 
covariates were calculated by exposure status (interpregnancy interval category and by 
history of recurrent miscarriage). 
We examined the possibly non-linear association between interpregnancy 
interval and ASD occurrence nonparametrically with restricted cubic splines (22). Tests 
for non-linearity used the likelihood ratio test comparing the model with only the linear 
term to the model with linear and cubic spline terms. 
We used generalized linear models, specifically log-binomial regression, to 
directly calculate crude and adjusted prevalence ratios (PR) of ASD (overall and for 
autism alone) with IPI length as the primary predictor. To identify the set of covariates 
to be included in the final adjusted model, covariates were independently added to the 
crude model and the variable with the largest change in PR for any interpregnancy 
interval category among those exhibiting a change of >10% was retained. A similar 
process was employed with successive models until further inclusion of additional 
covariates resulted in a change in PR that was less than 10%. Since none of the 
individual covariates tested met the definition of confounder, the results are presented 
only for the crude and the fully adjusted models. The reference category for these 
analyses was comprised of subjects with interpregnancy intervals of 30-35 months 
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duration, a category selected because it exhibited the lowest prevalence across IPI 
categories. Effect measure modification by outcome of the preceding pregnancy (live 
birth; pregnancy loss) and maternal age for those with a preceding live birth (<25 years; 
~25 years) was evaluated via stratification. We also fit a fully adjusted linear regression 
model for the association between interpregnancy interval and ASD for interval less 
than 18 months. 
Log-binomial regression methods were also used to directly calculate crude and 
adjusted prevalence ratios of ASD with history of loss as the primary predictor. The 
reference category for these analyses was comprised of multigravida with no history of 
loss. Decisions regarding which covariates to retain in the final multivariable regression 
model were made in a manner similar to that described above for the interpregnancy 
interval evaluation. Again, none of the covariates assess were significant confounders, 
so crude and fully adjusted models are presented. 
Crude models were estimated both including and excluding subjects with missing 
covariate information. Results were not appreciably different, thus model unadjusted 
results utilizing the entire study population are presented to preserve precision. 
Stratified analyses by the outcome of the preceding pregnancy (live birth; pregnancy 
loss) and maternal age (:::;30 years; >30 years) were used to assess effect measure 
modification. 
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4.3.6. Sensitivity Analyses 
An ASD diagnosis in an older ch ild may alter a mother's subsequent childbearing 
and in associated with an increased ASD risk in younger siblings. Therefore, we 
performed a sub-analysis of the association with interpregnancy interval restricted to 
deliveries for which older siblings were not identified in the El database as having an 
ASD diagnosis. This analysis was restricted to mothers who had their first pregnancy 
during the period 2000-2008 since El diagnosis data were only available for 2000-2011. 
. Using information contained in the birth certificate, we were able to classify study 
subjects by the outcome of the preceding pregnancy as either a live birth or a pregnancy 
loss. However, a preceding pregnancy loss could be a stillbirth, miscarriage or elective 
termination and are not differentiated on the birth certificate. There may be differential 
effects of interpregnancy interval on the occurrence of ASD for each specific type of 
loss. Thus, in an effort to evaluate a more homogeneous group, we used longitudinally 
linked fetal death records to identify previous stillbirths and performed a supplementary 
stratified analysis in which the strata for preceding pregnancy loss included only 
miscarriages and terminations. Likewise, we evaluated the association between number 
of previous pregnancy losses and ASD occurrence excluding stillbirths. 
It is possible that there were inaccuracies in the recording of the dates of last live 
birth on the birth certificate therefore we verified the date of last live birth documented 
on the birth record for second pregnancies against the birth records for first pregnancies 
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to the same mother. We performed a sub-analysis restricted to those where the dates 
used to calculate interpregnancy interval could be verified as accurate. 
4.4. RESULTS 
4.4.1. Characteristics of the Study Population 
Among 410,299 singleton live births from 2000 to 2008 to MA residents who had 
at least one previous pregnancy, we identified a total of 3002 children enrolled in the 
Early Intervention program by 3 years of age for an autism spectrum disorder (81.7% 
male, 18.3% female). 
The prevalence of early autism spectrum disorder diagnoses among the study 
population by selected characteristics is provided in Table 4.1. The prevalence of ASD 
increased nearly two-fold over the study period, from approximately 49 per 10,000 
singleton live births in 2000 to 97 per 10,000 singleton live births in 2008. ASD 
diagnoses were generally more common among children of mothers who had fewer 
previous live births, were over 35 years of age, heavy smokers, or had a pre-pregnancy 
history of a seizure disorder, diabetes or hypertension. ASD diagnoses were somewhat 
less common among children of mothers who were Asian/Pacific Islander or had less 
than a high school education. 
Distributions of selected characteristics by interpregnancy interval are presented 
in Table 4.2. Compared to mothers with interpregnancy intervals of 24-59 months, 
mothers with shorter interpregnancy intervals were younger, had fewer previous 
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pregnancies, and were more likely to have smoked or have received treatment for 
infertility. They were less likely to have pre-pregnancy diabetes or hypertension, or to 
have a preceding pregnancy that resulted in a live birth. 
Distributions of selected characteristics by maternal history of pregnancy loss are 
presented in Table 4.3. Mothers with a history of pregnancy loss and no previous live 
births were generally younger, had fewer previous pregnancies, and were more likely to 
have received treatment for infertility. 
4.4.2. Association between lnterpregnancy Interval and ASD Occurrence 
Conditional restricted cubic spline regression revealed that the association 
between interpregnancy interval and ASD occurrence was nonlinear and J-shaped (p-
value for test for curvature <0.0001; overall significance of curve <0.0001), with 
extremes in maternal interpregnancy interval being associated with the largest 
increases in ASD risk (Figure 4.1). 
The crude and adjusted prevalence ratios for ASD in relation to interpregnancy 
interval are presented in Table 4.4. Overall, maternal interpregnancy intervals <18 
months were associated with an increase in ASD among offspring compared to intervals 
of 30-35 months. The adjusted prevalence ratios ranged from 1.9 (95% Cl: 1.6, 2 .4) for 
interpregnancy intervals less than 6 months to 1.4 (95% Cl: 1.6, 1.7) for intervals of 12-
17 months. For intervals less than 18 months the association was linear (p <0.001, f3= -
0.00034); for each added month of interpregnancy interval the prevalence of ASD 
decreased by 3.4 per 10,000. Intervals of 60 months or longer were also associated with 
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a modest increase in ASD (aPR: 1.4, 95% Cl: 1.2, 1.7). There was no significant variation 
in ASD prevalence ratios for interpregnancy intervals of 18-59 months. Findings were 
similar when the analysis was restricted to study subjects with no history of ASD among 
older siblings (Table 4.5) and to second pregnancies for which dates used to calculate 
interpregnancy interval were verified against the birth records for the first pregnancy 
(Table 4.6). When early years (2000-2002} and later years (2003-2008) were analyzed 
separately, the same trends were observed, but the associations were slightly stronger 
in early years (Table 4.7). 
The crude and adjusted prevalence ratios for ASD in relation to interpregnancy 
interval stratified by the outcome of the preceding pregnancy are presented in Table 
4.8. Among mothers whose preceding pregnancy resulted in a live birth, interpregnancy 
intervals <18 months were associated with a 40-150% higher ASD prevalence among 
offspring. In contrast, we observed no association between shorter interpregnancy 
interval and ASD occurrence when the preceding pregnancy outcome was a miscarriage, 
elective termination or stillbirth. Long interpregnancy intervals (60 or months) were 
associated with a modest increase in ASD regardless of the outcome of the preceding 
pregnancy. Results were unchanged after restricting the strata for preceding pregnancy 
loss to include only spontaneous and elective terminations (Table 4.9). 
The crude and adjusted prevalence ratios for ASD in relation to interpregnancy 
interval stratified by maternal age are presented in Table 4.10. This assessment was 
restricted to women whose preceding pregnancy was a live birth, since maternal age is 
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associated with pregnancy loss. lnterpregnancy intervals less than 18 months were 
associated with higher risk of ASD regardless of maternal age. However, slightly 
stronger associations between short interpregnancy and ASD occurrence were observed 
for mothers less than 25 years of age than those 25 years or older. Intervals 60 months 
or longer were associated with a modest increase in ASD only among mothers 25 years 
or older. 
4.4.2. Association between Maternal History of Pregnancy Loss and ASD Occurrence 
The crude and adjusted prevalence ratios for ASD in relation to maternal history of 
pregnancy loss are presented in Table 4.11. Overall, there was a modest increase in ASD 
among offspring of multigravida with a history of pregnancy loss and no prior live birth 
compared to those with no history of loss (aPR: 1.5, 95% Cl: 1.3, 1.7). The increase was 
only apparent for women with fewer than 3 pregnancy losses and no previous live 
births. When we restricted pregnancy losses to include only spontaneous and elective 
terminations, associations were slightly attenuated (Table 4.12). 
4.5. DISCUSSION 
lnterpregnancy intervals shorter than 18 months and longer than 60 months 
were associated with increased risk of autism spectrum disorder compared with 
intervals 18-59 months. For intervals less than 18 months, the association was linear; 
for each added month of interpregnancy interval the prevalence of ASD decreased by 
3.4 per 10,000. We also found a modest increase in ASD risk among offspring of women 
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with history of pregnancy loss and no previous live births. 
Our findings relating short interpregnancy intervals to a modest elevation in ASD 
risk are consistent with those of others. In an evaluation of singleton full siblings 
identified among California births from 1992 to 2002, Cheslack-Postava et al. (7) 
reported an inverse association between interpregnancy interval and the risk of autism 
among second-born children. The strongest association was observed for pregnancies 
spaced less than one year apart (OR: 3.4, 95% Cl: 3.0, 3.8). More recently, a similar, but 
slightly weaker, association with short interpregnancy interval was reported using 
nationwide wide registry data on siblings born in Norway (8). Intervals shorter than 9 
months (OR: 2.2, 95% Cl: 1.4, 3.3) and 9-11 months (OR: 1.7, 95% Cl: 1.1,2.6) were 
associated with an increase in autistic disorder in the second-born sibling. The previous 
studies evaluated the relationship between short intervals and ASD risk only between 
first and second born siblings. Our study extends the association to all consecutive live 
births regardless of birth order. 
Short intervals may be a marker for a deficiency in nutritional reserves needed to 
support normal fetal development (23) . Maternal stores of important micronutrients 
decline during pregnancy and, although most rebound relatively shortly after delivery 
some including folate and vitamin 03 may take several months (24, 25). Furthermore, 
nutritional deficiency and stress are known to elevate inflammatory cytokines (17). 
Maternal folic acid and vitamin D deficiencies and elevated pro-inflammatory cytokine 
levels, particularly interleukin-6, have been implicated in neurologic deficits and 
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developmental disorders (26-28). An association between short interpregnancy intervals 
and increased ASD occurrence is plausible based on evidence that poor maternal 
nutritional status and stress have a negative impact on neurodevelopment (29-31). 
In supplementary analysis, Gunnes et al {8) showed the association between 
short intervals and autistic disorder among offspring to be stronger in mothers who did 
not use folic acid supplements before or during pregnancy providing support for the 
nutritional depletion hypothesis. Results of our stratified analyses offer some additional 
support. In the current study, we observed a stronger association with short intervals 
among mothers less than 25 years of age than among older moms. Young mothers may 
represent a subpopulation that require longer intervals to replenish nutritional stores 
between pregnancies given increased nutritional requirements for their own growth 
and development compared with older mothers (13). We also found an elevated risk for 
ASD in relation to short interpregnancy intervals following a preceding live birth, but no 
association with short intervals following a miscarriage or termination. Very short 
pregnancies such as those resulting in a miscarriage or termination may be less 
nutritionally demanding and result in little depletion of maternal reserves. 
Our observation of elevated ASD risk with intervals longer than 60 months is 
consistent with the U-shaped pattern between interpregnancy interval and autistic 
disorder observed by Gunnes et al. (8). The mechanism for such an association is likely 
distinct from that for short intervals and may be related to advanced parental age and 
subfertility. 
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Strengths of our study include a large sample size with low proportions of 
missing values for all variables. Use of the PELL data system and MA Early Interventions 
program for identification of ASD represents another strength of our study as it 
facilitated analyses of over 9 years of MA resident births. However, there are potential 
limitations related to the administrative nature of the data. Some covariate information 
captured from the birth certificate may not have been accurately recorded. Although 
reproductive history information has been shown to be more reliably captured, than 
information on maternal medical conditions (32), it is possible that there were 
inaccuracies in the pregnancy histories and associated dates resulting in some incorrect 
interpregnancy interval estimates. However, results of a sub-analysis restricted to 
second born children with validated interpregnancy intervals (i.e., relevant birth 
certificate information was verified against the birth certificate of the first born child) 
were consistent with findings for the whole study population. Unlike autism, Asperger's 
disorder is often diagnosed at ages older than three years. Thus, children with 
Asperger's disorder included in this study may be the more severe cases and any results 
may not be generalizable to the broader Asperger's community. 
In conclusion, the PELL data system provided the ability to link vital records for 
consecutive pregnancies to Early Intervention records enabling us to evaluate the risk 
for ASD in relation to interpregnancy interval and maternal history of pregnancy loss. 
Our results suggest that extremes in interpregnancy interval and previous pregnancy 
93 
loss among primapara may be associated with modest increases in the risk for ASD 
among offspring. 
4.6. REFERENCES 
1. Conde-Agudelo A, Rosas-Bermudez A, Kafury-Goeta AC. Birth spacing and risk of 
adverse perinatal outcomes: a meta-analysis. Journal of the American Medical 
Association 2006;295{15}:1809-23. 
2. Getz KD, Anderka MT, Werler MM, et al. Short interpregnancy interval and 
gastroschisis risk in the National Birth Defects Prevention Study. Birth Defects 
Research Part A Clinical and Molecular Teratology 2012;94{9):714-20. 
3. Kwon S, Laze-Escalante M, Villaran MV, et al. Relationship between 
interpregnancy interval and birth defects in Washington State. Journal of 
Perinatology 2012;32{1):45-50. 
4. Todoroff K, Shaw GM. Prior spontaneous abortion, prior elective termination, 
interpregnancy interval, and risk of neural tube defects. American Journal of 
Epidemiology 2000;151{5):505-11. 
5. Villamor E, Sparen P, Cnattingius 5. Risk of oral clefts in relation to prepregnancy 
weight change and interpregnancy interval. American Journal of Epidemiology 
2008;167(11):1305-11. 
6. Dodds L, Fell DB, Shea 5, et al. The role of prenatal, obstetric and neonatal 
factors in the development of autism. Journal of Autism and Developmental 
Disorders 2011;41(7):891-902. 
7. Cheslack-Postava K, Liu K, Bearman PS. Closely spaced pregnancies are 
associated with increased odds of autism in California sibling births. Pediatrics 
2011;127(2):246-53. 
8. Gunnes N, Suren P, Bresnahan M, et al. lnterpregnancy interval and risk of 
autistic disorder. Epidemiology 2013;24(6):906-12. 
9. Hvidtjorn D, Grove J, Schendel D, et al. Risk of autism spectrum disorders in 
children born after assisted conception: a population-based follow-up study. 
Journal of Epidemiology & Community Health 2011;65(6):497-502. 
94 
10. Lyall K, Pauls DL, Spiegelman D, et al. Fertility therapies, infertility and autism 
spectrum disorders in the Nurses' Health Study II. Paediatric and Perinatal 
Epidemiology 2012;26(4):361-72. 
11. Maimburg RD, Vaeth M. Do children born after assisted conception have less risk 
of developing infantile autism? Human Reproduction 2007;22(7) :1841-3. 
12. Buchmayer S, Johansson S, Johansson A, et al. Can association between preterm 
birth and autism be explained by maternal or neonatal morbidity? Pediatrics 
2009;124(5):e817-25. 
13. King JC. The risk of maternal nutritional depletion and poor outcomes increases 
in early or closely spaced pregnancies. Journal of Nutrition 2003;133(5 Suppl 
2):1732S-6S. 
14. Buehler MR. A proposed mechanism for autism: an aberrant neuroimmune 
response manifested as a psychiatric disorder. Medical Hypotheses 
2011;76(6):863-70. 
15. Cannell JJ. Autism and vitamin D. Medical Hypotheses 2008;70(4):750-9. 
16. Parker-Athill EC, Tan J. Maternal immune activation and autism spectrum 
disorder: interleukin-6 signaling as a key mechanistic pathway. Neurosignals 
2010;18(2):113-28. 
17. Patterson PH. Immune involvement in schizophrenia and autism: etiology, 
pathology and animal models. Behavioural Brain Research 2009;204(2):313-21. 
18. Calleja-Agius J, Jauniaux E, Pizzey AR, et al. Investigation of systemic 
inflammatory response in first trimester pregnancy failure. Human Reproduction 
2012;27(2):349-57. 
19. Christiansen OB, Nielsen HS, Kolte AM . Inflammation and miscarriage. Seminars 
in Fetal & Neonatal Medicine 2006;11(5):302-8. 
20. Laird SM, Tuckerman EM, Li TC. Cytokine expression in the endometrium of 
women with implantation failure and recurrent miscarriage. Reproductive 
BioMedicine Online 2006;13(1):13-23. 
21. Wilson R, Jenkins C, Miller H, et al. Abnormal cytokine levels in non-pregnant 
women with a history of recurrent miscarriage. European Journal of Obstetrics & 
Gynecology and Reproductive Biology 2004;115(1):51-4. 
95 
22. Durrleman S, Simon R. Flexible regression models with cubic splines. Statistics in 
Medicine 1989;8(5):551-61. 
23. King M, Bearman P. Diagnostic change and the increased prevalence of autism. 
International Journal of Epidemiology 2009;38(5):1224-34. 
24. Bruinse HW, van den Berg H. Changes of some vitamin levels during and after 
normal pregnancy. European Journal of Obstetrics & Gynecology and 
Reproductive Biology 1995;61(1}:31-7. 
25. Holmes VA, Barnes MS, Alexander HD, et al. Vitamin D deficiency and 
insufficiency in pregnant women: a longitudinal study. British Journal of Nutrition 
2009;102(6}:876-81. 
26. Georgieff MK. Nutrition and the developing brain : nutrient priorities and 
measurement. American Journal of Clinical Nutrition 2007;85(2):614S-20S. 
27. Grant WB, Soles CM. Epidemiologic evidence supporting the role of maternal 
vitamin D deficiency as a risk factor for the development of infantile autism. 
Dermato-Endocrinology 2009;1(4}:223-8. 
28. Smith SE, Li J, Garbett K, et al. Maternal immune activation alters fetal brain 
development through interleukin-6. Journal of Neuroscience 2007;27(40):10695-
702. 
29. Bale TL, Baram TZ, Brown AS, et al. Early life programming and 
neurodevelopmental disorders. Biological Psychiatry 2010;68(4):314-9. 
30. Brown AS, Susser ES. Prenatal nutritional deficiency and risk of adult 
schizophrenia. Schizophrenia Bulletin 2008;34(6):1054-63. 
31. Talge NM, Neal C, Glover V. Antenatal maternal stress and long-term effects on 
child neurodevelopment: how and why? Journal of Child Psychology and 
Psychiatry 2007;48(3-4):245-61. 
32. DiGiuseppe DL, Aron DC, Ranbom L, et al. Reliability of birth certificate data: a 
multi-hospital comparison to medical records information. Maternal and Child 
Health Journal2002;6(3}:169-79. 
96 
Table 4.1. Prevalence of early autism spectrum disorder diagnoses by 
selected characteristics among singleton live births to mothers who had at 
least one previous pregnancy, Massachusetts 2000-2008 
Autism Spectrum Disorder 
Characteristic Prevalence N n (per 10,000 
live births) 
Year of delivery 
2000 47284 230 48.6 
2001 47791 259 54.2 
2002 47614 300 63.0 
2003 46404 337 72.6 
2004 45083 358 79.4 
2005 44017 345 78.4 
2006 44561 375 84.2 
2007 44236 380 85.9 
2008 43309 418 96.5 
Sex of index child 
female 209709 2436 116.2 
male 200588 566 28.2 
I'V1aternal age 
less than 20 years 9607 42 43.7 
20-24 years 55053 349 63.4 
25-29 years 92060 633 68.8 
30-34 years 139503 1011 72.5 
35-39 years 92983 751 80.8 
40 years and older 21093 216 102.4 
Paternal age 
less than 20 years 3299 17 51 .5 
20-24 years 28426 182 64.0 
25-29 years 62057 463 74.6 
30-34 yea[S 114358 787 68.8 
35-39 years 101559 773 76.1 
40 years and older 57755 524 90.7 
missing 42845 256 59.8 
I'V1arital Status 
married to father 294530 2125 72.1 
married, not to father 3915 31 79.2 
not married 111843 846 75.6 
missing 11 0 0.0 
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Table 4.1. (continued) Prevalence of early autism spectrum disorder 
diagnoses by selected characteristics among singleton live births to mothers 
who had at least one previous pregnancy, Massachusetts 2000-2008 
Autism Spectrum Disorder 
Characteristic Prevalence N n (per 10,000 
live births) 
Maternal race 
Non-Hispanic white 285516 2116 74.1 
Non-Hispanic black 34664 277 79.9 
Hispanic 55799 405 72.6 
Asian/pacific Islander 25457 143 56.2 
Other 8501 56 65.9 
missing 362 5 
Maternal education 
less than high school graduate 43096 246 57.1 
high school graduate 110174 858 77.9 
some college (<4 years) 93483 772 82.6 
4 or more years of college 163079 1121 68.7 
missing 467 5 
Maternal alcohol consumption (during pregnancy) 
any 9022 61 67.6 
none 400677 2936 73.3 
missing 600 5 
Maternal cigarette consumption (pre-pregnancy) 
0 cigarettes per day 346753 2460 70.9 
1-19 cigarettes per day 45190 348 77.0 
20 or more cigarettes per day 18356 194 105.7 
Maternal pre-pregnancy diabetes 
yes 3526 42 119.1 
no 405460 2949 72.7 
missing 1313 11 
Maternal chronic hypertension 
yes 5048 56 110.9 
no 403938 2935 72.7 
missing 1313 11 
Maternal seizure disorder 
yes 1219 19 155.9 
no 407767 2972 72.9 
missing 1313 11 
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Table 4.1. (continued) Prevalence of early autism spectrum disorder 
diagnoses by selected characteristics among singleton live births to mothers 
who had at least one previous pregnancy, Massachusetts 2000-2008 
Autism Spectrum Disorder 
Characteristic Prevalence N n (per 10,000 
live births) 
Maternal anemia 
yes 15424 113 73.3 
no 393562 2878 73.1 
missing 1313 11 
Fertility treatment 
yes 3968 33 83.2 
no 405076 2958 73.0 
missing 1255 11 
Number of previous pregnancies 
1 211283 1640 77.6 
2 108464 741 68.3 
3 or more 90552 621 68.6 
Number of previous live births 
0 45737 420 91.8 
1 227249 1714 75.4 
2 or more 137277 868 63.2 
missing 36 0 
History of pregnancy loss 
No losses, ~1 previous livebirths 277095 1924 69.4 
~1 losses, ~1 previous livebirths 87431 658 75.3 
~1 loss, no previous livebirths 45737 420 91.8 
missing 36 
Outcome of preceding pregnancy 
Live birth 325169 2304 70.9 
Miscarriage, stillbirth or termination 84956 698 82.2 
missing 174 0 
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Table 4.2. Distribution (%) of selected characteristics by interpregnancy interval length for singleton 
livebirths to mothers who had at least one previous pregnancy, Massachusetts 2000-2008 
lnterpregnancy Interval, months 
Characteristic <6 6-11 12-17 18-24 24-59 ~60 
(n=33,723) (n=50,734) (n=57,280) (n=47,136) (n=127,469 (n=62,124) 
Year of delivery 
2000 11.0 11.0 11.1 11.0 11.1 10.6 
2001 11.8 11.6 11.6 11.6 11.4 11.0 
2002 11.7 11.7 11.9 12.0 11.3 10.8 
2003 11.1 11.3 11.2 11.6 11.6 11.2 
2004 11.1 11.1 11.1 11.1 11.2 11.2 
2005 11.0 10.9 11.2 10.8 10.8 11.1 
2006 10.9 10.9 10.8 10.9 11.0 11.4 
2007 10.8 10.9 10.7 10.5 11.0 11.4 
1-' 2008 10.6 10.6 10.5 10.4 10.5 11.4 0 0 
Sex of Index Child 
male 50.9 50.9 51.0 51.2 51 .1 51.4 
female 49.1 49.1 49.0 48.8 48.9 48.6 
Maternal age 
less than 20 years 6.2 3.9 2.7 2.1 1.2 0.0 
20-24 years 19.5 15.6 13.0 13.0 14.3 5.0 
25-29 years 23.2 22.4 20.5 19.9 22.7 24.3 
30-34 years 29.7 34.3 38.4 38.4 33.0 33.2 
35-39 years 17.7 20.2 21.7 22.7 23.9 27.7 
40 years and older 3.6 3.6 3.7 3.8 4.9 9.8 
Table 4.2. (continued) Distribution (%)of selected characteristics by interpregnancy interval length for 
singleton livebirths to mothers who had at least one previous pregnancy, Massachusetts 2000-2008 
lnterpregnancy Interval, months 
Characteristic <6 6-11 12-17 18-24 24-59 ~60 
(n=33,723) (n=50,734) (n=57,280) (n=47,136) (n=127,469 (n=62,124) 
Paternal age 
less than 20 years 2.0 1.1 0.9 0.7 0.5 0.2 
20-24 years 10.7 8.2 6.5 6.3 6.7 3.9 
25-29 years 17.5 15.9 14.2 13.6 15.0 14.9 
30-34 years 27.0 29.7 32.0 31.7 27.1 23.6 
35-39 years 21.2 23.3 25.3 26.4 26.9 24.7 
40 years and older 11 .1 12.0 11.9 12.1 14.2 21 .6 
missing 10.5 9.8 9.2 9.1 9.5 11.1 
Marital Status 
f-lo 
married to father 67.8 75.5 80.0 79.9 73.4 60.5 0 
f-lo 
married, not to father 0.8 0.5 0.4 0.5 0.9 2.2 
not married 31.3 23.9 19.5 19.6 25.7 37.3 
missing 0.0 0.0 0.0 0.0 0.0 0.0 
Maternal race 
Non-Hispanic white 70.7 73.4 76.5 76.4 69.0 58.8 
Non-Hispanic black 7.9 7.2 5.9 5.9 7.8 12.3 
Hispanic 13.9 11.9 10.3 10.6 14.3 19.3 
Asian/pacific Islander 5.4 5.6 5.6 5.5 6.8 6.5 
Other 2.0 1.8 1.6 1.6 2.0 3.0 
missing 0.0 0.1 0.1 0.1 0.1 0.1 
Table 4.2. (continued) Distribution(%) of selected characteristics by interpregnancy interval length for 
singleton livebirths to mothers who had at least one previous pregnancy, Massachusetts 2000-2008 
lnterpregnancy Interval, months 
Characteristic <6 6-11 12-17 18-24 24-59 ~60 
(n=33,723) (n=50,734) (n=57,280) (n=47,136) (n=127,469 (n=62,124) 
Maternal education 
less than high school graduate 13.2 10.3 8.5 8.0 10.1 13.3 
high school graduate 27.3 23.6 21.2 22.0 27.7 35.5 
some college ( <4 years) 22.2 21.0 19.5 19.9 22.9 27.7 
4 or more years of college 37.2 45.0 50.6 50.0 39.3 23.3 
missing 0.1 0.1 0.1 0.1 0.1 0.1 
Maternal alcohol consumption (during pregnancy) 
any 2.1 2.2 2.3 2.3 2.2 2.2 
....., none 97.8 97.7 97.6 97.6 97.7 97.7 0 
N 
missing 0.1 0.1 0.1 0.1 0.1 0.2 
Maternal cigarette consumption (pre-pregnancy) 
any 17.3 0.1 11.3 11.5 14.9 20.2 
none 82.7 86.9 88.7 88.5 85.1 79.8 
Maternal pre-pregnancy diabetes 
yes 0.6 0.7 0.7 0.7 0.8 1.2 
no 99.2 99.0 99.1 99.1 98.9 98.4 
missing 0.2 0.3 0.2 0.2 0.3 0.3 
Maternal chronic hypertension 
yes 0.9 0.9 1.0 1.0 1.1 2.1 
no 98.9 98.8 98.8 98.8 98.6 97.6 
missing 0.2 0.3 0.2 0.2 0.3 0.3 
Table 4.2. (continued) Distribution(%) of selected characteristics by interpregnancy interval length for 
singleton livebirths to mothers who had at least one previous pregnancy, Massachusetts 2000-2008 
lnterpregnancy Interval, months 
Characteristic <6 6-11 12-17 18-24 24-59 ~60 
(n=33,723) (n=50,734) (n=57,280) (n=47,136) (n=127,469 (n=62,124) 
Maternal seizure disorder 
yes 0.4 0.3 0.3 0.3 0.3 0.4 
no 99.4 99.5 99.5 99.5 99.5 99.3 
missing 0.2 0.3 0.2 0.2 0.3 0.3 
Maternal anemia 
yes 4.9 3.8 3.3 3.2 3.7 4.3 
no 94.9 95.9 96.5 96.6 96.1 95.4 
missing 0.2 0.3 0.2 0.2 0.3 0.3 
...... Fertility treatment 0 
w yes 1.2 1.0 0.9 0.9 0.9 0.8 
no 98.6 98.8 98.8 98.9 98.9 98.9 
missing 0.2 0.2 0.3 0.2 0.2 0.3 
Outcome of preceding pregnancy 
Live birth 46.8 78.9 88.3 91.1 91.3 90.2 
Loss (miscarriage, stillbirth or terminatio1 53.2 21.1 11.7 8.9 8.7 9.8 
Number of previous pregnancies 
1 38.7 48.8 55.1 56.0 53.7 53.6 
2 28.5 25.8 24.1 25.3 27.1 27.7 
3 or more 32.8 25.4 24.1 25.3 27.1 27.7 
1-' 
0 
.+::> 
Table 4.2. (continued) Distribution (%) of selected characteristics by interpregnancy interval length for 
singleton livebi!"f:hs to mothers who had at least one previous pregnancy, Massachusetts 2000-2008 
lnterpregnancy Interval, months 
Characteristic < 6 6-11 12-17 18-24 24-59 ~60 
(n=33,723) (n=50,734) (n=57,280) (n=47,136) (n=127,469 (n=62,124) 
Number of previous live births 
0 22.8 9.3 5.6 4.6 4.7 7.6 
1 46.2 57.1 62.8 63.0 58.9 53.8 
2 or more 30.9 33.6 31.6 32.4 36.4 38.6 
missing 0.0 0.0 0.0 0.0 0.0 0.0 
History of pregnancy loss 
No losses, ~1 previous livebirths 37.4 64.2 74.0 77.2 78.9 79.9 
~1 losses, ~1 previous livebirths 39.7 26.4 20.4 18.2 16.4 12.5 
~1 loss, no previous livebirths 22.8 9.3 5.6 4.6 4.7 7.6 
1-' 
0 
U"1 
Table 4.3. Distribution (%) of selected characteristics by maternal history of pregnancy loss for singleton 
livebirths to mothers who had at least one previous pregnancy, Massachusetts 2000-2008 
Pregnancy History Prior to the Index Pregnancy 
Characteristic ~ 1 Loss, No Livebirths ~1 Loss, ~1 Livebirths No Losses, ~1 Livebirths 
(n=45,737 ) (n=87,431) (n=277,095 ) 
Year of delivery 
2000 12.4 12.7 11.0 
2001 11.7 11.6 11.7 
2002 12.2 12.0 11.4 
2003 11.3 11.2 11.4 
2004 11.1 10.8 11.0 
2005 10.1 10.3 11.0 
2006 10.6 10.4 11.0 
2007 10.3 10.6 10.9 
2008 10.4 10.3 10.6 
Sex of Index Child 
male 50.8 51.0 51.2 
female 49.2 49.0 48.8 
Maternal age 
less than 20 years 8.2 1.0 1.8 
20-24 years 21.7 12.4 12.4 
25-29 years 24.1 22.8 22.0 
30-34 years 27.3 31.9 35.8 
35-39 years 14.6 24.9 23.3 
40 years and older 4.1 7.0 4.7 
1-" 
0 
(J) 
Table 4.3. (continued) Distribution (%)of selected characteristics by maternal history of pregnancy loss for 
singleton livebi!"ths to mothers who had at least one previous pregnancy, Massachusetts 2000-2008 
Pregnancy History Prior to the Index Pregnancy 
Characteristic :2: 1 Loss, No Livebirths :2:1 Loss, :2:1 Livebirths No Losses, :2:1 Livebirths 
(n=45,737 ) (n=87,431) (n=277,095 ) 
Paternal age 
less than 20 years 2.5 0.5 0.6 
20-24 years 12.8 6.4 6.1 
25-29 years 19.2 14.7 14.6 
30-34 years 26.3 25.5 28.9 
35-39 years 16.5 25.1 26.0 
40 years and older 10.1 16.1 14.1 
missing 12.6 11.6 9.7 
Marital Status 
married to father 60.0 66.8 75.3 
married, not to father 0.6 1.5 0.9 
not married 39.4 31.7 23.8 
missing 0.0 0.0 0.0 
Maternal race 
Non-Hispanic white 72.2 67.8 69.7 
Non-Hispanic black 9.3 10.9 7.6 
Hispanic 9.4 13.8 14.2 
Asian/pacific Islander 6.6 5.2 6.4 
Other 2.4 2.2 2.0 
missing 0.1 0.1 0.1 
1-' 
0 
'-1 
Table 4.3. (continued) Distribution (%)of selected characteristics by maternal history of pregnancy loss for 
singleton livebirths to mothers who had at least one p-revious pregnancy, Massachusetts 2000-2008 
Pregnancy History Prior to the Index Pregnancy 
Characteristic ~ 1 Loss, No Livebirths ~1 Loss, ~1 Livebirths No Losses, ~1 Livebirths 
(n=45,737 ) (n=87,431) (n=277,095 ) 
Maternal education 
less than high school graduate 9.0 12.0 10.3 
high school graduate 26.6 29.3 26.1 
some college (<4 years) 25.4 25.8 21.4 
4 or more years of college 38.8 32.8 42.1 
missing 0.1 0.1 0.1 
Maternal alcohol consumption (during pregnancy) 
any 2.6 2.7 2.0 
none 97.3 97.2 97.9 
missing 0.1 0.1 0.1 
Maternal cigarette consumption (pre-pregnancy) 
any 24.4 21.3 12.2 
none 75.6 78.7 87.8 
Maternal pre-pregnancy diabetes 
yes 0.7 0.9 0.9 
no 99.0 98.9 98.8 
missing 0.3 1.1 0.3 
Maternal chronic hypertension 
yes 1.1 1.4 1.2 
no 98.6 98.3 98.5 
missing 0.3 0 .2 0.3 
I-' 
0 
00 
Table 4.3. (continued) Distribution (%)of selected characteristics by maternal history of pregnancy loss for 
singleton livebirths to mothers who had at least one previous pregnancy, Massachusetts 2000-2008 
Pregnancy History Prior to the Index Pregnancy 
Characteristic ~ 1 Loss, No Livebirths ~1 Loss, ~1 Livebirths No Losses, ~1 Livebirths 
(n=45,737 ) (n=87,431) (n=277,095 ) 
Maternal seizure disorder 
yes 0.4 0.4 0.3 
no 99.3 99.4 99.4 
missing 0.3 0.2 0.3 
Maternal anemia 
yes 3.9 4.6 3.5 
no 95.8 95.2 96.2 
missing 0.3 0.2 0.3 
Fertility treatment 
yes 2.6 1.1 0.7 
no 97.1 98.7 99.0 
missing 0.3 0.2 0.3 
Outcome of preceding pregnancy 
Live birth 0.0 55.0 100.0 
Pregnancy Loss 1 100.0 44.9 0.0 
Number of previous pregnancies 
1 71.1 0.0 64.5 
2 20.3 35.7 24.5 
3 or more 8.5 64.3 11.0 
1Pregnancy loss includes stillbirth, miscarriage, and elective termination 
Table 4.4. Crude and fully adjusted prevalence ratios for autism spectrum 
disorder in relation to interpregnancy interval length among singleton 
livebirths to mothers who had at least one previous pregnancy, 
Massachusetts 2000-2008 
lnterpregnancy 
Interval ASD Cases (n) Total (N) PRcrude (95% Cl) PRrun1 (95% Cl) 
<6 months 332 33269 1.83 (1 .51' 2.21) 1.93 (1 .58, 2.35) 
6-11 months 461 50052 1.69 (1.40, 2.03) 1 . 77 ( 1 .4 7' 2 .13) 
12-17 months 415 56620 1.34 (1.12, 1.62) 1.40 (1.16, 1.68) 
18-23 months 290 46663 1.14 (0.94, 1.39) 1.18 (0.97, 1.43) 
24-29 months 213 37497 1.04 (0.85, 1.29) 1.06 (0.86, 1.30) 
30-35 months 149 27379 reference reference 
36-41 months 121 21186 1.05 (0.83, 1.33) 1.04 (0.82, 1.31) 
42-47 months 88 15194 1.00 (0.77, 1.30) 1.00 (0.73, 1.27) 
48-53 months 72 13243 1.00 (0.75, 1.32) 1.00 (0.73, 1.28) 
54-59 months 62 10692 1.07 (0.79, 1.43) 1.01 (0.75, 1.36) 
60+ months 557 61232 1.67 (1.39, 1.99l 1.41 (1.17, 1.69l 
1full model adjusted for birth year, maternal age (continuous),race/ethnicity, marital 
status , education, alcohol consumption, pre-pregnancy smoking, history of diabetes, 
chronic hypertension, seizure disorder, anemia, fertility treatment, gravidity and outcome 
of the preceding pregnancy; ASD= autism spectrum disorder; PR=prevalence ratio 
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Table 4.5. Crude and fully adjusted prevalence ratios for autism spectrum 
disorder in relation to interpregnancy interval length among singleton 
livebirths to mothers who had at least one previous pregnancy -- restricted 
to study pregnancies in which no older sibling had an ASD diagnosis, 
Massachusetts 2000-2008 
lnterpregnancy 
Interval ASD Cases (n) Total (N) PRcrude (95% Cl) PRtu11 1 (95% Cl) 
<6months 116 10483 1.71 (1.26,2.31) 1.84(1.35,2.51) 
6-11 months 202 20935 1.52 (1.21, 1.90) 1.61 (1.28, 2.02) 
12-17 months 189 24897 1.06 (0.84, 1.34) 1.12 (0.88, 1.41) 
18-23 months 145 19018 1.03 (0.80, 1.32) 1.07 (0.83, 1.38) 
24-59 months 248 36420 reference reference 
60+ months 43 3392 2.22 (1.55, 3.17) 2.05 (1.42, 2.94) 
1full model adjusted for birth year, maternal age (continuous),race/ethnicity, marital 
status, education, alcohol consumption, pre-pregnancy smoking, histories of diabetes, 
chronic hypertension, seizure disorder, and anemia; ASD= autism spectrum disorder; 
PR=prevalence ratio 
110 
Table 4.6. Crude and fully adjusted prevalence ratios for autism spectrum 
disorder in relation to interpregnancy interval length between first and 
second singleton births, Massachusetts Resident Births 2000-2008 -
lnterpregnancy 
Interval ASD Cases (n) Total (N) PRcrude (95% Cl) PRtun1 (95% Cl) 
<6months 55 5109 1.62(1.29,2.02) 1.98(1.57,2.51) 
6-11 months 136 14232 1.41 (1.17, 1.70) 1.60 (1.32, 1.93) 
12-17months 123 18413 1.11 (0.91, 1.34) 1.24(1.02, 1.50) 
18-23months 92 14245 1.12(0.91,1.37) 1.22(0.99,1.50) 
24-59 months 171 27223 reference reference 
60+ months 36 2565 1.85 (1.34, 2.55) 1.55 (1.12, 2.15) 
1full model adjusted for birth year, maternal age (continuous),race/ethnicity, marital 
status, education, alcohol consumption, pre-pregnancy smoking, history of diabetes, 
chronic hypertension, seizure disorder, anemia, and fertility treatment; ASD= autism 
spectrum disorder; PR=prevalence ratio 
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Table 4.7. Crude and fully adjusted prevalence ratios for autism spectrum disorder 
in relation to interpregnancy interval length among singleton livebirths to mothers 
who had at least one previous pregnancy- stratified by year of delivery, 
Massachusetts 2000-2008 
Year of Delivery 2000-2002 
lnterpregnancy 
Interval ASD Cases (n) Total (N) PRcrude (95% Cl) PRtun1 (95% Cl) 
<6 months 98 11493 2.22 (1.73 , 2.84) 2.45 (1.87 , 3.21) 
6-11 months 130 17145 1.97 (1.57, 2.48) 2.10 (1.66 , 2.64) 
12-17 months 112 19540 1.49(1.17, 1.90) 1.53 (1 .20, 1.95) 
18-23 months 76 16163 1.23 (0.93, 1.61) 1.23 (0.94, 1.62) 
24--59 months 163 42542 reference reference 
60+ months 123 19858 1.61 (1.28, 2.04) 1.42 (1 .12, 1.81) 
Year of Delivery 2003-2008 
lnterpregnancy 
Interval ASD Cases (n) Total (N) PRcrude (95% Cl) PRtun1 (95% Cl) 
<6months 195 18088 1.65(1.42, 1.92) 1.74(1.48, 2.05) 
6-11 months 265 27276 1.55 (1.35, 1.77) 1.64 (1.43, 1.88) 
12-17 months 254 30717 1.26 (1.09, 1.45) 1.32 (1 .15, 1.53) 
18-23 months 185 25092 1.08 (0.92, 1.27) 1.13 (0.97, 1.33) 
24--59 months 4 77 68937 reference reference 
60+ months 376 34507 1.61 (1.42, 1.83) 1.37 (1.20, 1.56) 
1full model adjusted for birth year, maternal age (continuous),race/ethnicity, marital status , 
education, alcohol consumption, pre-pregnancy smoking, history of diabetes , chronic 
hypertension, seizure disorder, anemia, fertility treatment, gravidity and outcome of the preceding 
pregnancy; ASD= autism spectrum disorder; PR=prevalence ratio 
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Table 4.8. Crude and fully adjusted prevalence ratios for autism spectrum disorder 
in relation to interpregnancy interval length among singleton livebirths to mothers 
who had at least one previous pregnancy- stratified by outcome of the preceding 
pregnancy, Massachusetts 2000-2008 
Outcome of the Preceding Pregnancy= Live birth 
lnterpregnancy 
Interval ASD Cases (n) Total (N) PRcrude (95% Cl} PRruu1 (95% Cl) 
<6 months 187 15528 2.28 (1.83 , 2.85) 2.49 (2.00, 3.11) 
6-11 months 382 39472 1.84 (1.51 ' 2.24) 1.95 (1 .60, 2.37) 
12-17 months 359 49958 1.37 (1 .12, 1.67) 1.42 (1 .17, 1.74) 
18-23 months 260 42491 1.17 (0.94, 1.44) 1.20 (0.98, 1.48) 
24-29 months 186 34207 1.03 (0.83, 1.29) 1.05 (0.84, 1.31) 
30-35 months 131 25020 reference reference 
36-41 months 101 19391 0.99 (0.77, 1.29) 0.99 (0.76, 1.28) 
42-47 months 76 14737 0.99 (0.74, 1.31) 0.97 (0.73, 1.28) 
48-53 months 61 12149 0.97 (0.71 ' 1.30) 0.93 (0.69, 1.26) 
54-59 months 54 9759 1.06 (0.77, 1.45) 1.01 (0 .73, 1.38) 
60+ months 470 55228 1.62 (1.34 , 1.97) 1.37 (1.13, 1.67) 
Outcome of the Preceding Pregnancy= Pregnancy loss2 
lnterpregnancy 
Interval ASD Cases (n) Total (N) PRcrude (95% Cl) PRru 111 (95% Cl) 
<6 months 145 17741 1.07 (0.66, 1.74) 1.16 (0.71 , 1.89) 
6-11 months 79 10580 0.98 (0.59, 1.63) 1.04 (0 .62 , 1.73) 
12-17 months 56 6662 1.10 (0.65, 1.87) 1.15 (0.68, 1.96) 
18-23months 30 4172 0.94(0.52 , 1.69) 0.97(0.54,1 .74) 
24-29 months 27 3290 1.07 (0.60, 1.95) 1.09 (0.60, 1.98) 
30-35 months 18 2359 reference reference 
36-41months 20 1795 1.45(0.77 , 2.74) 1.40(0.74,2.64) 
42-47months 12 1457 1.08(0.52, 2.23) 1.02(0.49, 2.12) 
48-53 months 11 1094 1.31 (0.62, 2.76) 1.23 (0.58, 2.59) 
54-59 months 8 933 1.12 (0.49, 2.57) 1.04 (0.46, 2.40) 
60+ months 87 6004 1.89 (1.13, 3.12) 1.55 (0 .93, 2.58) 
1full model adjusted for birth year, maternal age (continuous),race/ethnicity, marital status, 
education, alcohol consumption, pre-pregnancy smoking , history of diabetes, chronic 
hypertension, seizure disorder, anemia, fertility treatment, and gravidity; ASD= autism 
spectrum disorder; PR=prevalence ratio 
2includes stillbirth, miscarriage, and elective termination 
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Table 4.9. Crude and fully adjusted prevalence ratios for autism spectrum disorder 
in relation to interpregnancy interval length among singleton livebirths to mothers 
who had at least one previous pregnancy- preceding outcome= pregnancy loss , 
Massachusetts 2000-2008 
Outcome of the Preceding Pregnancy= Pregnancy loss 1 
lnterpregnancy 
Interval ASD Cases (n) Total (N) PRcrude (95% Cl) PRti (95% Cl) 
<6 months 143 17579 1.06 (0.65, 1.73) 1.14(0.70, 1.88) 
6-11 months 79 10473 0.98 (0.59, 1.64) 1.05 (0.63, 1.74) 
12-17 months 56 6596 1.11 (0 .65, 1.88) 1.16 (0.68, 1.97) 
18-23 months 29 4140 0.91 (0.51 ' 1.64) 0.94 (0.53, 1.70) 
24-29 months 27 3274 1.08 (0.59, 1.95) 1.10 (0.61, 1.99) 
30-35 months 18 2350 reference reference 
36-41 months 19 1786 1.38 (0.73, 2.63) 1.33 (0.70, 2.53) 
42-47 months 12 1451 1.08 (0.52, 2.23) 1.02 (0.49, 2.12) 
48-53 months 11 1091 1.31 (0 .62, 2.76) 1.23 (0.58, 2.59) 
54-59 months 8 931 1.12 (0.49, 2.57) 1.04 (0.46, 2 .39) 
60+ months 87 5998 1.88 (1.13, 3.11) 1.54 (0.92, 2 .56) 
1 includes miscarriage and elective termination 
2 full model adjusted for birth year, maternal age (continuous ),race/ethnicity, marital status , 
education, alcohol consumption, pre-pregnancy smoking, history of diabetes, chronic 
hypertension, seizure disorder, anemia, fertility treatment, and gravidity; ASD= autism spectrum 
disorder; PR=prevalence ratio 
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Table 4.10. Crude and fully adjusted prevalence ratios for autism spectrum disorder 
in relation to interpregnancy interval length among singleton livebirths to mothers 
who had at least one previous pregnancy- stratified by maternal age, 
Massachusetts 2000-2008 
Maternal Age <25 ~ears, Precedinq Pregnane~ =live birth 
lnterpregnancy 
Interval ASD Cases (n) Total (N) PRcrude {95% Cl) PRtuu1 (95% Cl) 
<6 months 40 4677 2.71 (1.43, 5.17) 2.85 (1.49, 5.43) 
6-11 months 64 7120 2.86 (1.55, 5.29) 2.95 (1.59, 5.47) 
12-17 months 47 7126 2.10 (1 .12, 3.96) 2.14 (1 .13, 4 .03) 
18-23 months 35 5798 1.98 (1.03, 3.80) 1.94 (1.01' 3.75) 
24-29 months 16 4588 1.11 (0.53, 2.36) 1.13 (0 .53, 2.39) 
30-35 months 12 3847 reference reference 
36-41 months 14 3003 1.49 (0 .69 , 3.22) 1.50 (0 .69, 3.23) 
42-47 months 6 2263 0.85 (0.32, 2.26) 0.84 (0.32, 2.23) 
48-53 months 7 1759 1.27 (0.50, 3.22) 1.26 (0.56, 2.84) 
54-59 months 6 1220 1.57 (0.59, 4.19) 1.53 (0.58, 4.08) 
60+ months 9 2656 1.08 (0.46, 2.57) 1.06 (0.45, 2.52) 
Maternal Age >25 ~ears, Preceding Pregnane~ =live birth 
lnterpregnancy 
Interval ASD Cases (n) Total (N) PRcrude {95% Cl) PRtuu1 (95% Cl) 
<6 months 259 24711 2.37 (1.87, 3.02) 2.38 (1.87, 3.03) 
6-11 months 381 40278 1.75 (1.42, 2.17) 1.76 (1.43, 2.17) 
12-17 months 355 47692 1.29 (1 .05, 1.59) 1.31 (1 .06, 1.62) 
18-23 months 251 39577 1.09 (0.87, 1.36) 1.10 {0.88, 1.38) 
24-29 months 192 31944 1.01 (0 .80 , 1.28) 1.02 (0.81' 1.30) 
30-35 months 133 22832 reference reference 
36-41 months 101 17712 0.94 (0.71 ' 1.23) 0.94 (0.71 ' 1.23) 
42-4 7 months 79 13582 1.00 (0.75, 1.35) 0.98 (0.73, 1.32) 
48-53 months 63 11239 0.93 (0 .68, 1.29) 0.90 (0.65, 1.24) 
54-59 months 55 9285 0.99 (1.27, 1.89) 0.96 (0.69, 1.35) 
60+ months 543 58121 1.55 (1.26, 1.89) 1.43 (1.16, 1.75) 
1full model adjusted for birth year, race/ethnicity, marital status, education, alcohol consumption, 
pre-pregnancy smoking, history of diabetes , chronic hypertension, seizure disorder, anemia, 
fertility treatment,and gravidity; ASD= autism spectrum disorder; PR=prevalence ratio 
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Table 4.11 Crude and adjusted prevalence ratios for autism spectrum disorders in relation to history of 
pregnancy loss among multigravida, Massachusetts 2000-2008 
~1 loss, no previous livebirths 
1 previous loss, no previous livebirths 
2 previous loss, no previous livebirths 
3+ previous loss, no previous livebirths 
~1 losses, ~1 previous livebirths 
1 previous loss, ~1 previous livebirths 
2 previous losses , ~1 previous livebirths 
3+ previous losses , ~1 previous livebirths 
No losses, ~1 previous livebirths 
ASD Cases (n) Total (N) 
280 28192 
204 20210 
56 5591 
20 2391 
590 74878 
363 46674 
141 18026 
86 10178 
1890 270900 
PRcrude (95% Cl) 
1.32 (1.19, 1.47) 
1.31 (1.16, 1.48) 
1.46 (1.19, 1.79) 
1.07 (0.74, 1.54) 
1.08 (0.99, 1.18) 
1.09 (0.99, 1.21) 
1.05 (0.89, 1.24) 
1.12 (0.91, 1.37 
reference 
PRtun1 (95% C I) 
1.39 (1.25, 1.55) 
1.42 (1.25, 1.61) 
1.48 (1.20, 1.82) 
1.01 (0.70, 1.46) 
1.04 (0.95, 1.13) 
1.08 (0.97, 1.20) 
1.03 (0.87, 1.21) 
1.06 (0.86 1.29) 
reference 
1full model adjusted for birth year, maternal age (continuous), race/ethnicity, marital status, education, alcohol consumption, pre-
...., pregnancy smoking, history of diabetes, chronic hypertension, seizure disorder, anemia, and fertility treatment; ASD= autism 
~ spectrum disorder; PR=prevalence ratio 
Table 4.12 Crude and adjusted prevalence ratios for autism spectrum disorders in relation to history of 
pregnancy loss among multigravida -excluding women with a history of stillbirth, Massachusetts 2000-2008 
ASD Cases (n) Total (N) PRcrude (95% Cl) PRtun1 (95% Cl) 
~1 loss, no previous livebirths 277 27788 1.33 (1 .19, 1.47) 1.47 (1.29, 1.67) 
1 previous loss, no previous livebi rths 204 19943 1 .33 ( 1 .17, 1 .50) 1 .43 ( 1 .26, 1 .62) 
2 previous losses, no previous livebirths 53 5509 1 .43 ( 1.16, 1 . 76) 1 .44 ( 1 .17, 1. 78) 
3+ previous loss, no previous livebirths 20 2336 1.09 (0.76, 1.57) 1.03 (0 .72, 1.49) 
~11osses . ~1previouslivebirths 584 74017 1.08(0.99,1.18) 1.07(0.98,1.18) 
1 previous loss, ~1 previous livebirths 359 46169 1.09 (0.98, 1.21) 1.07 (0.96, 1.19) 
2 previous losses, ~1 previous livebirths 140 17809 1.06 (0.90, 1.24) 0.99 (0.84, 1.16) 
3+ previous losses , ~1 previous livebirths 85 10039 1.12 (0.91 , 1.38) 0.99 (0.80, 1.21) 
No losses, ~1 previous livebirths 1882 269584 reference reference 
...... 
1full model adjusted for birth year, maternal age (continuous), race/ethnicity, marital status, education, alcohol consumption, pre-
~ pregnancy smoking, history of diabetes, chronic hypertension, seizure disorder, anemia, and fertility treatment; ASD= autism 
spectrum disorder; PR=prevalence ratio 
...... 
...... 
00 
Figure 4.1. Restricted cubic spline regression analysis assessing nonlinearity of the association between interpregnancy 
interval and occurrence of autism spectrum disorders 
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5. CONCLUSIONS 
Numerous studies have assessed genetic and postnatal factors and their associations 
with autism spectrum disorder (ASD) occurrence, but the effects of maternal factors 
shaping the fetal environment have been less well researched. This dissertation 
examined some of these factors. 
In study 1, we assessed the associations of maternal infection, asthma and 
autoimmune disease with the occurrence of ASD among singletons born into the UK 
General Practice Research Database from 1993 through 2008. We found a modest 
association with bacterial infection (aOR: 1.5, 95% Cl: 1.1, 2.0), in particular skin and 
urinary tract infections. We also observed a small increase in ASD risk in relation to 
maternal asthma (aOR: 1.3, 95% Cl: 1.1, 1.5), which was consistent across the ASD 
subtypes. No association was found between maternal autoimmune disease and ASDs 
overall, but subtype specific analyses. 
In study 2, we also performed a case-control study nested within the GPRD to 
evaluate the association between maternal pre-pregnancy body mass index and ASD 
occurrence. We observed a nonlinear association between maternal BMI and ASD that 
suggested extremes in maternal BMI (underweight and obesity) may be associated with 
modest increases in the risk for ASD among offspring. However, the relationship 
between maternal BMI and ASD risk differed by maternal age. Maternal underweight 
was significantly associated with an increase in ASD only among mothers over 30 years 
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of age. In contrast, maternal obesity was associated with increased risk for ASD 
irrespective of age, but the relative association was most prominent among mothers 
under 30 years of age. 
In study 3, we explored autism risk in offspring in relation to factors related to 
maternal reproductive history. Specifically, we assessed the associations of short 
interpregnancy interval (IPI) and maternal history of pregnancy loss with the occurrence 
of ASD diagnosed by age 3 years among individuals born in Massachusetts from 2000-
2008 to multigravida. The association between maternal IPI and ASD occurrence was 
non-linear and J-shaped, where IPI lengths less than 18 months and longer than 60 
months were associated with an increased risk for ASD. The association with short IPI 
was restricted to consecutive live births and stronger for younger mothers than older 
mothers. A history of pregnancy loss was associated with a modest increase in ASD risk 
among multigravida, but there was no obvious trend that would suggest recurrent loss 
was more detrimental than a single loss. 
As stated in the Introduction, there are a number of theories relating maternal 
factors to fetal neurodevelopment. Our findings lend support to the theories that 
maternal immune activation and maternal nutritional depletion play a role in the 
etiology of ASD among offspring. Further studies in larger populations with the ability to 
explore biomarkers of inflammation and concentrations of important micronutrients 
and to explore genetic interaction will help to further evaluate validity of these theories. 
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